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Abstract 
Metabolic engineering of Escherichia coli for the production of coenzyme Q10 
Corinne Cluis 
Concordia University, 2014 
Coenzyme Q10 is required for respiratory electron transport and protects 
biological membranes against oxidative damage. As coenzyme Q10 supplements are used 
to treat or to alleviate symptoms associated with an increasing number of health 
conditions, there is growing interest in the development of bioprocesses for its 
production. The biosynthesis of coenzyme Q10 involves the condensation of an 
isoprenoid, decaprenyl diphosphate, with an aromatic compound, para-hydroxybenzoate,
followed by a series of modifications of the aromatic moiety of the molecule via the 
ubiquinone pathway. Escherichia coli naturally produces coenzyme Q8, but replacement 
of its octaprenyl diphosphate synthase by a decaprenyl diphosphate synthase is sufficient 
to eliminate the production of coenzyme Q8 and favor the synthesis of coenzyme Q10.  
A rational genetic engineering approach was used to create a strain of E. coli
capable of producing high levels of coenzyme Q10. First, the endogenous octaprenyl 
diphosphate synthase gene was deleted and functionally replaced by a decaprenyl 
diphosphate synthase-encoding gene derived from Sphingomonas baekryungensis.
Additionally, this strain was engineered to produce elevated levels of para-
hydroxybenzoate by over-expressing genes encoding enzymes of the E. coli shikimate 
pathway. The production of isoprenoid was increased by introducing a heterologous 
mevalonate pathway. Decaprenyl diphosphate and para-hydroxybenzoate were further 
iv
directed toward the ubiquinone pathway by overexpressing a para-hydroxybenzoate 
prenyltransferase. The resulting recombinant strain was capable of producing elevated 
levels of coenzyme Q10. In order to further enhance production of this antioxidant, an 
investigation into the interplay between coenzyme Q10 biosynthesis and primary 
metabolism was conducted. This investigation revealed a link between sorbitol 
catabolism and coenzyme Q10 production in the engineered strain. Moreover, abrogating 
carbon flux to acetate by selected gene knock-outs also enhanced coenzyme Q10 
accumulation. However, the engineered strains developed through this research were 
found to be highly unstable, leading to high variability in coenzyme Q10 production. This 
instability was hypothesized to result from the burden exerted by the engineered aromatic 
and foreign mevalonate pathways on primary metabolism. As a result, further 
optimization of these engineered strains of E. coli will be required in order to develop a 
suitable platform for coenzyme Q10 production. 
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1Chapter 1. Introduction 
1.1 Thesis statement  
The goal of this project was to engineer the metabolism of the enterobacterium 
Escherichia coli for the production of the commercially-valuable molecule, coenzyme 
Q10 (CoQ10). As will be detailed in Chapter 1, the biosynthetic pathway leading to the 
formation of CoQ10 is complex, with precursors stemming from different branches of 
metabolism and a great number of enzymes involved. Moreover, the biological function 
of this molecule is linked to aerobic respiration and energy production, which 
presupposes strict control mechanisms to ensure that appropriate levels are present in the 
cell membrane. Efforts to obtain higher CoQ10 yields in microbes using genetic 
engineering have been scattered, often narrowed on one branch of the biosynthetic 
pathway (Huang et al., 2011; Zahiri et al., 2006b; Zhang et al., 2007). Some 
improvements obtained were enhanced due to enrichment of the fermentation medium or 
modifications in growth conditions, demonstrating E. coli’s capacity to accumulate 
higher concentrations of CoQ10, but offering little insight into the underlying biological 
mechanism(s) responsible for the reported enhanced accumulation levels.  
My driving hypothesis was that a systematic identification and upregulation of 
gene expression for rate-limiting steps in CoQ10 biosynthesis would result in 
unprecedented accumulation of this molecule in E. coli. Corollary to this, I believed that 
the investigation of metabolic or physiological factors influencing the synthesis of 
CoQ10 in E. coli would provide useful insight for the design of novel engineering 
2strategies to improve CoQ10 production in microbes. Throughout my research, the 
identification and characterization of such limiting factors primed over the achievement 
of high CoQ10 contents in engineered E. coli strains. I used genetic tools, such as 
recombinant plasmids, gene deletions and insertions, and defined alterations in primary 
metabolism using the growth medium, in order to push carbon flux towards CoQ10 
biosynthesis. As such, more than industrially-fit solutions, the strains engineered through 
this project serve to establish proof-of-concept demonstrations of novel ways to increase 
CoQ10 biosynthesis in microbes. 
1.2 Physiological functions and applications of coenzyme Q10 in medicine 
Coenzyme Qn (CoQn), also known as ubiquinone, is a lipid-soluble molecule 
with high redox potential. It is formed of a benzoic group conjugated to a long isoprenoid 
chain with a varying number (n) of isoprene units (Figure 1.1).  
Figure 1.1 Structure of coenzyme Q10. 
Humans naturally produce CoQ10, which plays a major role in the transfer of 
electrons between respiratory complexes of the electron transport chain, located within 
the inner mitochondrial membrane (Kroger and Klingenberg, 1973). CoQ10 also acts as 
an antioxidant, protecting membranes and proteins from oxidation by scavenging free 
radicals and by regenerating pools of tocopherols (Lass and Sohal, 1998; Martin et al., 
2007; Yoshida et al., 2006). There is evidence that CoQ10 is involved in the 
quinoid group isoprenoid side-chain
3transcriptional regulation of genes, some of which play roles in inflammatory responses 
and in cholesterol metabolism (Schmelzer et al., 2007; Schmelzer et al., 2010). CoQ10 
supplements have been demonstrated to have positive effects on patients suffering from 
certain cardio-vascular conditions, such as congestive heart failure and acute myocardial 
infarction (Hodgson et al., 2002; Shults et al., 2002; Singh et al., 1998; Yang et al., 
2010).  Additionally, it has been shown that patients taking statin drugs (3-hydroxy-3-
methyl-glutaryl-CoA reductase inhibitors) to reduce cholesterol levels may suffer from 
diminished blood ubiquinone levels, which may be linked to muscle problems like 
myopathy and myositis that could be alleviated through CoQ10 supplementation (Schaars 
and Stalenhoef, 2008). Furthermore, early research has suggested that CoQ10 
supplementation may benefit patients suffering from male infertility, neurodegenerative 
disease and diabetes-associated nephropathy (Mancini and Balercia, 2011; Sourris et al., 
2012; Yang et al., 2010). Another major application of CoQ10 is as an ingredient of 
dermatological ointments, due to evidence that its topological application can reduce 
wrinkle formation (Inui et al., 2008).   
This growing demand for CoQ10 from the pharmaceutical and cosmetic sectors 
has led to intensified efforts to decrease the cost of CoQ10 industrial production. Possible 
production methods for CoQ10 include: chemical synthesis (Negishi et al., 2002), semi-
chemical synthesis using solanesol (Lipshutz et al., 2005), or microbial fermentation 
using yeasts or bacteria.  Microbial biosynthesis offers several advantages over chemical 
and semi-chemical synthesis, including specificity towards the all-trans biologically 
active isomer of CoQ10, and the reduced production of environmentally hazardous waste.  
Indeed, the viability of a microbial biosynthesis approach has been demonstrated by 
4companies, such as Kaneka Corporation, that have already commercialized biologically-
produced CoQ10 obtained from fermentation using proprietary yeast strains.  In recent 
years, considerable research has emerged in attempts to isolate suitable microbial strains 
for the development of cost-effective bioprocesses for CoQ10 production. 
1.3 Quinone diversity between and within species 
The function and overall structure of ubiquinone is well conserved across species, 
but the length of its isoprenoid side-chain varies.  For instance, humans mainly synthesize 
CoQ10 while rodents predominantly generate CoQ9; the budding yeast Saccharomyces 
cerevisiae makes CoQ6, but the closely related Schizosaccharomyces pombe makes 
CoQ10. Quinone diversity is also found among prokaryotes, where the ubiquinone chain 
length varies between eight-isoprene units (i.e. Escherichia coli, CoQ8), nine-isoprene 
units (i.e. Acetobacter aceti, CoQ9) or ten-units (i.e. Paracoccus denitrificans, CoQ10). 
In addition, prokaryotes may produce alternative quinone types bearing a naphthalene 
head group, depending on their species. These naphthoquinones include menaquinone 
and demethylmenaquinone. Typically, strictly aerobic gram-negative species of bacteria 
contain solely ubiquinone, while gram-negative facultative aerobic bacteria use both 
ubiquinone and menaquinone or demethylmenaquinone. Gram-positive bacteria, on the 
other hand, appear to largely use menaquinone or demethylmenaquinone (Collins and 
Jones, 1981).   
51.4 Physiological functions of ubiquinone in prokaryotes 
Similar to eukaryotes, prokaryotes use ubiquinone as an electron carrier during 
respiration. In E. coli ubiquinone is used when O2 or nitrate are the final electron 
acceptors. Menaquinone and demethylmenaquinone, which have lower midpoint 
potentials than ubiquinone, are used during anaerobic respiration when final electron 
acceptors, such as fumarate, have a low midpoint potential (Ingledew and Poole, 1984).
The redox state of ubiquinone also serves as a cue for cells to initiate aerobic or anaerobic 
cell functions. For example, in E. coli, the oxidized form of CoQ8 has been demonstrated 
to act as a direct negative signal for the Arc two-component signal transduction system 
(Georgellis et al., 2001). This regulatory switch consists of the membrane-associated 
sensor kinase ArcB, which undergoes autophosphorylation under anaerobic conditions, 
turning on its kinase activity. Activated ArcB then phosphorylates the transcription 
regulator ArcA, resulting in the transcription of genes involved in anaerobic metabolism 
and in the repression of genes taking part in aerobic metabolism.  Therefore, by inhibiting 
the autophosphorylation of ArcB during aerobiosis, CoQ8 thus prevents the onset of 
anaerobic metabolism (Georgellis et al., 2001; Malpica et al., 2004). Also in E. coli,
CoQ8 participates in disulfide bond formation by providing oxidizing power to the 
cytoplasmic membrane protein DsbB, which then oxidizes the periplasmic enzyme DsbA, 
responsible for introducing disulfide bonds to newly synthesized proteins (Bader et al., 
2000). The various roles for CoQ8 that have been elucidated in E. coli demonstrate the 
importance of quinones in many facets of cellular function.  
61.5  Biosynthesis of ubiquinone in prokaryotes  
Genetic and biochemical studies have led to almost complete elucidation of the 
CoQ8 biosynthesis pathway in E. coli. Homologues of genes involved in this pathway 
were identified in several other bacterial species, suggesting that ubiquinone synthesis is 
highly conserved among prokaryotes (Figure 1.2).
The aromatic core of the CoQn molecule is derived from the shikimate pathway, 
which starts with the condensation of erythrose-4-phosphate (E4P) and 
phosphoenolpyruvate (PEP). The shikimate pathway leads to the production of the 
aromatic intermediate chorismate, a precursor for several essential aromatic molecules 
including folate and aromatic amino acids, which is converted to para-hydroxybenzoate 
(PHB) by the chorismate lyase UbiC. PHB, the first committed intermediate to 
ubiquinone biosynthesis, is then prenylated with an isoprenoid of varying length, 
depending on the species (Figure 1.2).  
In prokaryotes, long chain isoprenoids are derived from the 2-C-methyl-D-
erythritol 4-phosphate (MEP) pathway. The MEP pathway leads to the formation of two 
isoprenoid building blocks, isopentenyl diphosphate (IPP) and dimethylallyl diphosphate 
(DMAPP). DMAPP then serves as a primer for the elongation of a fifteen-carbon 
isoprenoid by the farnesyl diphosphate (FPP) synthase IspA, which successively 
condenses IPP molecules to form FPP. This fifteen-carbon isoprenoid is the substrate for 
a polyprenyl diphosphate synthase, which further elongates the isoprenoid chain that will 
eventually form the prenyl side-chain constituent for ubiquinone synthesis (Figure 1.2).
E. coli endogenously expresses an octaprenyl diphosphate (OPP) synthase, IspB, leading 
7to the formation of OPP and finally to CoQ8. In this way, the product formation 
catalyzed by a given polyprenyl synthase determines the chain length of the ubiquinone 
produced in each organism. Indeed, the heterologous expression in a microbial host of a 
polyprenyl diphosphate synthase, catalyzing the formation of an isoprenoid of n subunits, 
is sufficient for the accumulation of CoQn species with the corresponding chain length, n. 
For instance, the expression in E. coli of sdsA, encoding the solanesyl diphosphate 
synthase from Rhodobacter capsulatus, results in the production of both CoQ8 from the 
endogenous IspB and CoQ9 from the heterologous SdsA (Okada et al., 1997a).  
The enzymatic steps downstream of PHB and isoprenoid formation, leading to the 
formation of ubiquinone, further described in this paragraph, will be referred to here as 
the ubiquinone pathway (Figure 1.2). The prenylation of PHB is carried out by an integral 
membrane protein, UbiA, forming the quinoid intermediate 3-polyprenyl-4-
hydroxybenzoate (Young et al., 1972). In E. coli, UbiA competes for OPP with MenA, 
which directs OPP towards the biosynthesis of menaquinone and demethylmenaquinone. 
The product of UbiA is then decarboxylated into the intermediate 2-polyprenylphenol. In 
E. coli, two decarboxylases, UbiD and UbiX, participate in this reaction (Cox et al., 1969; 
Gulmezian et al., 2007; Leppik et al., 1976a). The next step of the ubiquinone pathway 
consists of the hydroxylation of 2-polyprenylphenol into 2-polyprenyl-6-hydroxyphenol. 
Genetic studies in E. coli had previously linked this reaction to the product of ubiB (Poon 
et al., 2000). However, UbiB is a kinase-like protein with no homology to known 
hydroxylases. A more recent study demonstrates that UbiI, an enzyme with structural 
characteristics of flavin adenine dinucleotide-dependent monooxygenases, is the main 
enzyme responsible for the hydroxylation of 2-polyprenylphenol (Hajj Chehade et al., 
82013). The product of this reaction, 2-polyprenyl-6-hydroxyphenol, is then methylated by 
UbiG, forming 2-polyprenyl-6-methoxyphenol, which is further hydroxylated by UbiH to 
form 2-polyprenyl-6-methoxy-1,4-benzoquinol (Alexander and Young, 1978; Hsu et al., 
1996; Young et al., 1973). A second methyltransferase, UbiE, transfers a methyl group 
from S-adenosylmethionine to 2-polyprenyl-6-methoxy-1,4-benzoquinol, resulting in 2-
polyprenyl-3-methyl-6-methoxy-1,4-benzoquinol (Lee et al., 1997; Young et al., 1971). 
The hydroxylase UbiF then adds a hydroxyl group, forming 2-polyprenyl-3-methyl-5-
hydroxy-6-methoxy-1,4-benzoquinol (Young et al., 1971). Finally, this last intermediate 
is methylated in a second reaction carried out by UbiG, completing the formation of 
CoQn, in its reduced form (Leppik et al., 1976a; Stroobant et al., 1972) (Figure 1.2).  
All ubiquinone pathway intermediates have a hydrophobic isoprenoid side chain 
that localizes them to the cytoplasmic membrane. It follows that a number of ubiquinone 
biosynthetic enzymes are or have been predicted to be membrane-associated (Bhasin et 
al., 2005; Claros and von Heijne, 1994; Leppik et al., 1976a; Leppik et al., 1976b; Young 
et al., 1972). Furthermore, strains with mutations in ubiB, ubiG or ubiH accumulate the 
intermediate 2-octaprenylphenol (Alexander and Young, 1978; Poon et al., 2000; Young 
et al., 1973), indicating that a loss of activity of any of these three enzymes blocks the 
hydroxylation of this intermediate (Figure 1.2). This phenotype suggests interdependency 
or a complex between these three proteins. Such a complex has indeed been isolated from 
the cytoplasmic membranes and was capable of converting 2-octaprenylphenol to CoQ8 
in vitro. It is hypothesized to remain in standby position during anaerobiosis and resume 
the conversion of 2-octaprenylphenol to ubiquinone upon transition to aerobic conditions 
(Knoell, 1979; Knoell, 1981). There is also increasing evidence for the existence of such 
9a complex in S. cerevisiae, and given the similarities between the two pathways, a related 
complex might be functional in E. coli (Baba et al., 2004; Gin and Clarke, 2005; Hsu et 
al., 2000; Marbois et al., 2005). Studies with yeast also suggest that ubiquinone is 
synthesized in two phases: the first phase involves interactions between multiple proteins 
and CoQ6, leading to the formation of 2-hexaprenyl-6-methoxy-1,4-benzoquinol, while 
the second phase, ultimately leading to the conversion of 2-hexaprenyl-6-methoxy-1,4-
benzoquinol into CoQ6 (Figure 1.2), is triggered by the transition to stationary phase and 
by linolenic acid-induced oxidative stress  (Padilla et al., 2009). The activity of Coq7p, 
the monooxygenase responsible for the conversion of 2-hexaprenyl-6-methoxy-1,4-
benzoquinol to 2-hexaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinol, is 
modulated by its phosphorylation state: phosphorylated Coq7p is deactivated and thus 
indirectly leads to a decrease in CoQ6 accumulation, while dephosphorylated Coq7p 
results in increased CoQ6 synthesis (Martin-Montalvo et al., 2011). This suggests that in 
S. cerevisiae, the biosynthesis of ubiquinone is modulated post-translationally by protein 
kinases and phosphatases, thereby fine-tuning quinone production with the respiratory 
needs of the cell. Supporting a similar model in prokaryotes, E. coli studies using the 
translation inhibitor chloroamphenicol suggest that the increase in cellular ubiquinone 
pools that follow a switch from anaerobic to aerobic conditions can be attributed to a 
post-translational mechanism (Shestopalov et al., 1997).  
Overall, the biosynthesis of ubiquinone is complex, incorporating precursors 
generated from different branches of central metabolism, requiring a great number of 
enzymes working in synchrony and a myriad of genes whose timely expression is 
essential for the proper unfolding of the pathway. Understanding of the different steps of 
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this biosynthetic pathway, as well as of the regulatory mechanisms underlying its 
functionality, is key to rationally engineer an industrially-viable biocatalyst capable of 
high CoQ10 yields.  
Figure 1.2 Biosynthetic pathway of ubiquinone in prokaryotes  
Enzyme names and intermediates are inferred from research studies in E. coli. The chain 
length of isoprenoids and ubiquinone pathway intermediates is kept unspecified (n) to 
generalize the pathway model to encompass all prokaryotes. (1) erythrose-4-phosphate; (2) 
phosphoenolpyruvate; (3) 3-deoxy-arabino-heptulosonate 7-phosphate; (4) shikimate; (5)
chorismate; (6) para-hydroxybenzoate; (7) pyruvate; (8) glyceraldehyde-3-phosphate; (9)
1-deoxy-D-xylulose-5-phosphate; (10) demethylallyl diphosphate; (11) isopentenyl 
diphosphate; (12) farnesyl diphosphate; (13) polyprenyl diphosphate; (14) 3-polyprenyl-4-
hydrobenzoate; (15) 2-polyprenylphenol; (16) 2-polyprenyl-6-hydroxyphenol; (17) 2-
polyprenyl-6-methoxyphenol; (18) 2-polyprenyl-6-methoxy-1,4-benzoquinol; (19) 2-
polyprenyl-3-methyl-6-methoxy-1,4-benzoquinol; (20) 2-polyprenyl-3-methyl-5-hydroxy-
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6-methoxy-1,4-benzoquinol; (21) ubiquinol; (22) ubiquinone (CoQn). Abbreviations: ATP, 
adenosine triphosphate; ADP, adenosine diphosphate; NADPH/NADP+, nicotinamide 
adenine dinucleotide phosphate; SAM, S-adenosylmethionine; SAH, S-
adenosylhomocysteine. 
1.6 Natural producers of CoQ10 
CoQ10 is produced in naturally high quantities by several microorganisms 
including strains of gram-negative soil bacteria such as Rhizobium radiobacter (a.k.a. 
Agrobacterium tumefaciens), Paracoccus denitrificans, and Protomonas extorquens, as 
well some photoautotrophs including Rhodobacter sphaeroides (a.k.a. 
Rhodopseudomonas sphaeroides), and yeast species such as Sporidiobolus johnsonii, 
which accumulate intracellular CoQ10 to levels between 0.8 and 3.3 mg/g dry cell weight 
(DCW) (Dixson et al., 2011; Urakami and Hori-Okubo, 1988; Yoshida et al., 1998).  
Furthermore, the innate CoQ10 content of a number of naturally producing strains 
has been increased through chemical mutagenesis. In order to select high CoQ10-
producing mutant strains, a number of indirect phenotypes were used as surrogate 
screens. For example, R. radiobacter mutants that could produce up to 2-fold higher 
CoQ10 content than the wild type parental strain were selected for their ability to grow 
on daunomycin, menadinone (quinone-like molecules generating hydroxyl radicals) 
and/or the methionine antagonist ethionine (Farr and Kogoma, 1991; Myers et al., 1987; 
Yoshida et al., 1998). The mutations resulting in enhanced CoQ10 production in such 
mutants remain largely undetermined. However, in one instance, it was determined that 
an R. radiobacter mutant strain with a high CoQ10 content displayed up-regulated 
expression levels of a number of genes involved in the tricarboxylic acid (TCA) cycle 
(Koo et al., 2010). In another example of screening for enhanced CoQ10 producers, R. 
12
sphaeroides mutants were chosen based on their colony colour as a surrogate selection 
for increased CoQ10 accumulation.  In this case, a green colony colour was used to 
indicate reduced accumulation of cellular carotenoids, which are synthesized from the 
same isoprenoid precursors as CoQ10 and could indicate the allocation of more cellular 
isoprenoid resources towards CoQ10 production (Sakato et al., 1992; Urakami and Hori-
Okubo, 1988; Yoshida et al., 1998). It is also possible that CoQ10 synthesis was up-
regulated in carotenoid-reduced mutant strains in order to balance the loss of one 
antioxidant (carotenoid), with another (CoQ10).  The selected mutants display 1.3 to 3-
fold increases in CoQ10 production compared to their parental strains.   
1.7 R. radiobacter as a production platform for CoQ10 
Despite their high CoQ10 contents, most natural producers of CoQ10, wild type 
or mutant, are unsuitable for industrial applications due to their limited growth rate and 
yields. For instance, even under optimized fermentor conditions, the cell mass obtained 
with a mutant strain of R. sphaeroides did not exceed 18.6 g DCW/L (Kien et al., 2010). 
One exception is R. radiobacter, which is gaining popularity as a host for the production 
of CoQ10. R. radiobacter mutants isolated for their improved CoQ10 content can be 
cultivated in fermentors at densities exceeding 65 g DCW/L (Ha et al., 2007a). There are 
two accounts where R. radiobacter was engineered for higher CoQ10 production by 
either over-expressing its (DXP) synthase 1-deoxy-D-xylulose 5-phosphate or its 
glyceraldehyde-3-phosphate dehydrogenase (Koo et al., 2010; Lee et al., 2007). 
However, most improvements in CoQ10 titers were obtained by modifications in culture 
growth conditions and media composition (Ha et al., 2009; Ha et al., 2007a; Ha et al., 
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2007b). Various optimization strategies involving media composition and growth 
conditions are presented in section 1.10.
1.8 E. coli as a production platform for CoQ10 
E. coli is commonly used as a model for the heterologous production of CoQ10 in 
microbes. It is an attractive host for development as an industrial production platform due 
to the following: (1) its robust fermentation characteristics, including fast growth rate; (2) 
its amenability to genetic engineering and; (3) the extensive knowledge that exists 
regarding its ubiquinone pathway and primary metabolism.  As a result, rational genetic 
engineering strategies have been developed to allow production of CoQ10 in E. coli, and 
are presented in section 1.9. These strategies have led to improvements in the yields of 
CoQ10 obtained from engineered E. coli strains (Table 1.1). However, such yields still 
fall below those obtained from natural CoQ10 producers, such as R. radiobacter,
indicating that the factors limiting CoQ10 accumulation in E. coli bear further 
investigation. 
1.9 Engineering strategies for high CoQ10 production in microbes 
1.9.1 Heterologous expression of a decaprenyl diphosphate synthase 
As mentioned above (section 1.3), wild type E. coli produces CoQ8 as its 
predominant ubiquinone molecule.  However, it is possible for E. coli to produce CoQ10 
by the expression of a heterologous decaprenyl diphosphate (DPP) synthase (DPS), 
which catalyzes the sequential condensation reaction between IPP and FPP to form DPP 
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(Figure 1.2). For example, the dps genes from CoQ10-producing bacterial species, 
including R. radiobacter, R. sphaeroides, and Gluconobacter suboxydans, have been 
isolated and expressed in E. coli (Lee et al., 2004; Park et al., 2005; Zhang et al., 2007).
Additionally, a given heterologous DPS must be expressed in a ΔispB background, where 
expression of E. coli’s endogenous OPP synthase has been abolished, in order to 
eliminate CoQ8 synthesis in favor of CoQ10 production (Choi et al., 2009; Huang et al., 
2011; Kim et al., 2006; Lee et al., 2004; Okada et al., 1998; Park et al., 2005; Takahashi 
et al., 2003; Zahiri et al., 2006a; Zahiri et al., 2006b).  E. coli ΔispB strains expressing a 
foreign DPS accumulate CoQ10, along with varying levels of CoQ8 and CoQ9, 
depending on the DPS expressed (Okada et al., 1998; Takahashi et al., 2003; Zahiri et al., 
2006a). Most bacteria surveyed to date produce minor amounts of differing CoQn forms 
with shorter-length isoprenoid side-chains in addition to their main ubiquinone species, 
suggesting that DPS enzymes generally make other prenyl diphosphates in addition to 
DPP. The production of shorter or longer ubiquinone species in E. coli strains engineered 
for CoQ10 production poses a problem from an industrial point of view due to the 
reduced yields of CoQ10 that result when precursors are channeled towards non-desired 
products and the extra costs associated with purifying CoQ10 from additional quinone 
species.
1.9.2 Increasing production of precursors of CoQ10 
As described in section 1.5, the formation of ubiquinone in bacteria occurs 
through condensation between the aromatic molecule PHB, derived from the shikimate 
pathway, and the long-chain isoprenoid, DPP, formed via the MEP pathway. A current 
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strategy to improve the heterologous production of CoQ10 in E. coli is to overexpress 
rate-limiting enzymes leading to the production of these precursor molecules (Zahiri et 
al., 2006b; Zhang et al., 2007). 
1.9.2.1 Increasing the production of isoprenoid precursors
The first step of the MEP pathway is the condensation of pyruvate and 
glyceraldehyde-3-phosphase to yield DXP, catalyzed by the DXP synthase, DXS (Figure 
1.2). The heterologous production of the carotenoid lycopene in E. coli, which also 
requires isoprenoid precursors, has been improved by the overexpression of DXS (Harker 
and Bramley, 1999; Kim and Keasling, 2001). Using the same rationale, higher titers of 
CoQ10 have been achieved by overexpressing the dxs gene isolated from Pseudomonas 
aeruginosa in E. coli strains engineered for CoQ10 production (Choi et al., 2009; Kim et 
al., 2006). Up to 1.8-fold improvement in specific CoQ10 content was obtained in strains 
over-expressing both DPS and DXS compared to those expressing solely DPS (Table 
1.1).  An alternative to the overexpression of the endogenous MEP pathway in E. coli is 
to express a heterologous mevalonate pathway, generally found in eukaryotes. Synthetic 
mevalonate pathways are typically divided into two parts: an upper pathway that converts 
acetyl-CoA to mevalonate and a lower pathway that converts mevalonate into DMAPP 
and IPP. Both parts of the pathway can be co-expressed, enabling the formation of 
isoprenoids from acetyl-CoA. Alternatively, one can express the lower part of the 
pathway alone and supplement the growth medium with mevalonate to enable the 
production of IPP and DMAPP. The expression of the lower part of the mevalonate 
pathway in E. coli strains expressing a recombinant dps has led to two-fold improvements 
in CoQ10 accumulation, while the expression of both the upper and lower sections of the 
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pathway has thus far led to more modest improvements (1.5-fold) (Zahiri et al., 2006b) 
(Table 1.1).
1.9.2.2 Increasing the production of aromatic precursors
As described in section 1.5, the first committed aromatic precursor to ubiquinone, 
PHB, is formed through the shikimate pathway leading to chorismate (Figure 1.2). As 
chorismate is a precursor molecule in several essential metabolic routes, the conversion 
of chorismate to PHB may limit the rate of production of ubiquinone in E. coli. It has 
been shown that the overexpression of the chorismate lyase UbiC in engineered E. coli
increased the production of CoQ10 when the downstream PHB polyprenyltransferase, 
UbiA, was coexpressed (Zhang et al., 2007; Zhu et al., 1995). Another study reports that 
the exogenous addition of PHB improved CoQ10 production by two-fold, but only when 
the supply of isoprenoid precursors was concomitantly increased (Zahiri et al., 2006b).
Overall, these experiments suggest that the availability of PHB becomes rate-limiting to 
CoQ10 production mainly when the supply of isoprenoid increases, resulting in more 
DPP available for CoQ10 biosynthesis, or when the activity of UbiA goes up, leading to 
an increased flux of PHB to the ubiquinone pathway. 
1.9.2.3  Overexpression of the ubiquinone pathway
In E. coli it has been shown that the rate-limiting step to CoQ10 production 
occurs at the condensation reaction between the aromatic PHB and isoprenoid DPP, 
catalyzed by UbiA (Zhang et al., 2007; Zhu et al., 1995). The overexpression of UbiA, 
along with DPS, resulted in as much as a 3.4-fold increase in CoQ10 content compared to 
strain expressing DPS alone (Zhang et al., 2007).  Additionally, to overcome any 
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potentially limiting steps stemming from the native regulatory mechanisms, the ubiB,
ubiG and ubiH genes have been overexpressed in E. coli.  The overexpression of these 
genes had only a limited effect on ubiquinone production (Table 1.1) (Zhang et al., 2007; 
Zhu et al., 1995). However, the E. coli background strains used in these experiments were 
subjected to endogenous regulation of aromatic and isoprenoid precursors. Therefore, it is 
possible that limited carbon flux to the ubiquinone pathway resulted in the modest 
increases in ubiquinone content reported in these studies. When precursors are produced 
in excess, CoQ10 biosynthesis may then become limited by the activity of one or more 
enzymes of the ubiquinone pathway. 
1.9.3 Improving CoQ10 production using central metabolism 
As an alternative or complementary strategy to increase carbon flux towards 
CoQ10 production in engineered E. coli strains, one may consider introducing alterations 
into the central metabolic pathways. The glycolysis intermediate glyceraldehyde-3-
phosphate is, along with pyruvate, an initial building block of the MEP pathway, which 
in turn supplies the isoprenoid precursors necessary for the prenylation of ubiquinone 
(Figure 1.2). By deleting pykA and pykF, coding for pyruvate kinases, and over-
expressing the PEP carboxykinase Pck, carbon flux can be redirected towards 
glyceraldehyde-3-phosphate, which favours increased flux through the MEP pathway 
(Farmer and Liao, 2001). Applying this approach to CoQ10 production, a 1.7-fold 
increase in CoQ10 content was obtained in an E. coli strain expressing a G. suboxydans
DPS (Huang et al., 2011) (Table 1.1).  
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Another attractive strategy to improve the production of a molecule of interest in 
a microbial host is to manipulate the levels of redox cofactors required for its synthesis. 
The production of one molecule of CoQ10 from glucose requires 21 molecules of 
nicotinamide adenine dinucleotide phosphate (NADPH) (20 molecules from the MEP 
pathway and one NADPH from the shikimate pathway) (Figure 1.2). In order to increase 
the availability of NADPH, the nicotinamide adenine dinucleotide (NAD+)-dependent 
glyceraldehyde-3-phosphate dehydrogenase, GapA, of E. coli can be replaced with the 
NADP+-dependent glyceraldehyde-3-phosphate dehydrogenase, GapC, from Clostridium 
acetobutylicum (Huang et al., 2011; Martinez et al., 2008). When this approach was used 
to improve CoQ10 biosynthesis in engineered E. coli strains, a 1.25-fold increase in 
CoQ10 content was observed (Table 1.1). In a high CoQ10-producing mutant strain of R. 
radiobacter, a positive correlation was demonstrated between the NADH/NAD+ ratio and 
the specific CoQ10 content (Koo et al., 2010). Based on this finding, the native NAD+-
dependent GapA, was over-expressed to increase the NADH/NAD+ ratio and further 
improve CoQ10 production. This strategy resulted in a 25% increase in NADH/NAD+
and in over two-fold improvement in CoQ10 content (Koo et al., 2010) (Table 1.1). The 
results of these two studies, which both take advantage of glyceraldehyde-3-phosphate 
dehydrogenases to alter the pools of redox factors, appear somewhat conflicting (Huang 
et al., 2011; Koo et al., 2010). Nevertheless, these studies highlight the necessity to 
explore in more detail the relationship between central metabolism and CoQ10 
production in microbes. 
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E. coli DPSGsub N/A Isoprenoid 0.29 0.67 25.5 (Park et al., 2005)
E. coli DXS N/A Isoprenoid (MEP) ~0.80 N/A N/A
(Harker and 
Bramley, 1999)
E. coli DPSGsub ,DXS N/A
Isoprenoid 
(MEP) 0.94 0.94 46.1 (Kim et al., 2006)
E. coli DPSAtum,DXS ispB
Isoprenoid 
(MEP) 1.41 3.1 100










N/A Isoprenoid (mevalonate) 2.428 N/A N/A
(Zahiri et al., 
2006b)





glycolysis 0.44 0.01 0.31








glycolysis 0.45 0.02 0.37















3.24 2.82 5.64 (Huang et al., 2011)
E. coli DPSAtum,UbiA N/A
Isoprenoid, 
ubiquinone 0.51 N/A N/A
(Zhang et al., 
2007)
E. coli DPSAtum,UbiA, UbiC N/A
Isoprenoid, 
ubiquinone 0.59 1.55 50.29
(Zhang et al., 
2007)
E. coli DPSAtum,UbiG N/A
Isoprenoid, 
ubiquinone 0.19 N/A N/A
(Zhang et al., 
2007)
E. coli UbiC, UbiA N/A Ubiquinone ~0.45 N/A N/A (Zhu et al., 1995)
E. coli IspB, UbiC, UbiA N/A
Isoprenoid, 
ubiquinone ~0.80 N/A N/A (Zhu et al., 1995)
E. coli IspB, UbiC, UbiA, UbiB N/A
Isoprenoid, 





N/A Isoprenoid, ubiquinone ~0.95 N/A N/A (Zhu et al., 1995)
R. radiobacter GapA N/A Glycolysis 5.27 N/A N/A (Koo et al., 2010)
R. radiobacter DXS Isoprenoid 8.3 4.5 502.4 (Lee et al., 2007)
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1.10 Improving CoQ10 yields through growth conditions 
 As discussed in section 1.6, the CoQ10 content of natural producers, such as R. 
radiobater and R. sphaeroides has been improved by random mutagenesis and selection. 
However, because of the limited genetic tools available for these organisms, the rational 
genetic strategies that can be applied to E. coli are largely impractical. As a result, most 
research has focused on increasing CoQ10 production by fine-tuning the growth 
conditions of these organisms, both in flasks and in fermentors.  
Although there is still conflicting evidence on this matter (Wu et al., 2003), a 
number of reports have shown that CoQ10 production tends to increase under low 
aeration conditions, both in R. radiobacter and R. sphaeroides (Choi et al., 2005; Ha et 
al., 2007b; Seo and Kim, 2010; Yen and Chiu, 2007; Yen and Shih, 2009). For instance, 
the CoQ10 content of a mutant strain of R. radiobacter increased four-fold by reducing 
dissolved oxygen concentrations from 20 to 5% (Choi et al., 2005) (Table 1.2). As part of 
the electron transport chain, it is possible that CoQ10 levels are modulated by variations 
in the electron flux or in the proton gradient brought about by the limited oxygen supply. 
To test these possibilities, the effect of the cytochrome c oxidase inhibitor, azide, and of 
2,4-dinitrophenol, a proton ionophore that uncouples oxidative phosphorylation, on 
CoQ10 accumulation were assessed in R. radiobacter (Choi et al., 2005). The addition of 
2,4-dinitrophenol had no effect on CoQ10 accumulation, indicating that large-scale 
changes in the cellular proton gradient do not affect CoQ10 production (Choi et al., 
2005). The addition of increasing concentrations of sodium azide, on the other hand, 
correlated to increasing CoQ10 content of bacterial cultures (Choi et al., 2005; Seo and 
Kim, 2010). These results suggest that the restricted electron flux through the respiratory 
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chain brought about by low aeration conditions, mimicked by the azide treatment, 
triggers the synthesis of CoQ10. Though the precise mechanism behind this phenomenon 
is unclear, it has been hypothesized that when the transfer of electrons through the 
electron transport chain to the final acceptor is slowed by a decrease in oxygen 
availability, electrons are trapped in upstream constituents of the respiratory chain, 
potentially leading to an accumulation of the reduced form of CoQ10, CoQ10H2 (Bekker 
et al., 2007). Cells may thus be forced to synthesize more CoQ10 in order to fix this 
imbalance of CoQ10/CoQ10H2 (Choi et al., 2005). Alternatively, partial blockage of the 
respiratory chain may lead to an accumulation of toxic free electrons in the inner 
membrane, hence triggering the synthesis of more CoQ10 to scavenge these electrons 
(Choi et al., 2005).  
In addition to respiration, facultative photoautotrophs such as R. sphaeroides also 
use CoQ10 to transfer electrons from the reaction center to the cytochrome bc1 complex, 
within the photosynthetic apparatus (Vermeglio and Joliot, 1999). Growth of R.
sphaeroides under anaerobic/light conditions increased the specific CoQ10 content over 
four-fold compared to the level attained under aerobic/dark growth conditions (Table 
1.2). However, this growth strategy significantly decreased the growth rate of the already 
low biomass culture, therefore making it uncompetitive for industrial applications (Yen 
and Chiu, 2007).  Nevertheless, this finding suggests that the complete shutdown of 
respiration associated with the onset of photosynthetic reactions triggers the cells to 
accumulate more CoQ10 within their inner membrane. This observation, coupled with 
the CoQ10 accumulation that accompanies a slowed electron transport chain, yields 
22
strong evidence that hindering respiration is an effective strategy in increasing CoQ10 
productivity. 
Another successful strategy to improve CoQ10 yields in R. radiobacter was to 
increase the concentration of calcium in the growth media. It has been proposed that the 
increased Ca2+ concentration is a source of oxidative stress for the cell, triggering the 
onset of lipid peroxidation and the production of reactive oxygen species (Ha et al., 
2009). Because CoQ10 has well-documented antioxidant properties, it may therefore be 
likely that increasing its production is the natural response to such oxidative stress. 
Supporting this hypothesis, an oxidative stress challenge, mediated by the addition of 
hydrogen peroxide to R. radiobacter cultures, also results in increases in CoQ10 content 
(Seo and Kim, 2010). The selection of high CoQ10-producing mutants on free radical-
generating growth inhibitors, described in section 1.6, also supports this link between 
CoQ10 production and oxidative stress (Yoshida et al., 1998) . 
The effect of growth on select carbon and nitrogen sources on CoQ10 production 
has been explored in mutant strains of R. radiobacter. There is conflicting evidence of the 
impact that growth on different carbon sources has on accumulated CoQ10 content, with 
one study reporting sucrose, glucose and fructose as having a positive impact on CoQ10 
content compared to xylose, lactose and galactose (Koo et al., 2010), while another report 
shows no differences in CoQ10 content for growth on these carbon sources (Ha et al., 
2007b). Plant based nitrogen sources such as corn steep powder and soytone yielded the 
highest CoQ10 specific content compared to other nitrogen sources including yeast 
extract, meat extract and tryptone (Ha et al., 2007b; Koo et al., 2010). Overall, modifying 
growth conditions in order to modulate central metabolic processes appears to be an 
23
effective strategy in enhancing CoQ10 production in microbes (for further culture 
conditions that correspond to increased CoQ10 accumulation refer to Table 1.2).








ATTC4452 87.6 1.9 Not applicable




Maximal DO of 40 % 
(of air saturation) (Wu et al., 2003)
R. radiobacter 
ATCC4452 Not reported 5.3
Decreased DO, azide 
treatment (Choi et al., 2005)
R. radiobacter 
KCCM 10413 458 8.54
Fed-batch with sucrose 
as carbon source, pH 7.0 
and 0-10 % DO
(Ha et al., 2007b)
R. radiobacter 
KCCM 10413 638 9.71
Decreased sucrose 




(Ha et al., 2007a)
R. radiobacter 
KCCM 10413 763.7 11.84 CaCl2 supplementation (Ha et al., 2009)
R. radiobacter T6102 14.6 1.95 Decreased DO; H2O2and azide treatement 
(Seo and Kim, 
2010)
R. radiobacter A603-
35-gapA Not reported 5.27
Increased NADH/NAD+
ratio (Koo et al., 2010)
R. spheroides KY
8598 770 Not reported
Controlled agitation 
speed and oxygen supply
(Sakato et al., 
1992)
R. sphaeroides KY
4113 350 8.7 Decreased aeration




0 % DO and cultivation 
without light




Use of airlift bioreactor 
for low aeration




Fed-batch system with 
molasses at 1 % w/v (Yen et al., 2010)
S. johnsonii Not reported 10.5 Post log growth phase addition of PHB
(Dixson et al., 
2011)
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1.11 Thesis objectives  
Current literature offers hints regarding the biochemical steps and metabolite 
availability that most limit CoQ10 accumulation in microbes. Moreover, the modulation 
of biological processes such as catabolism, redox balance and respiration, all of which 
have links to the functions of ubiquinone, has the potential to increase the production of 
CoQ10 in E. coli. Based on this evidence, this thesis is structured around two objectives: 
1) To use rational design to address all known rate-limiting factors to CoQ10 
biosynthesis. In Chapter 2, I describe the steps taken to build a strain of E. coli capable of 
producing high levels of CoQ10, but most importantly, a strain where each pathway 
limiting carbon flux towards ubiquinone are addressed individually, in a systematic 
manner. 
2) To expand current knowledge on the physiological and/or metabolic factors 
limiting CoQ10 accumulation in E. coli. In Chapter 3, I investigate whether CoQ10 
production in engineered E. coli strains can be further enhanced by harnessing the 
bacteria’s capacity to direct carbon flow towards given directions either to fulfill its 
energy needs or to achieve redox balance.  
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Chapter 2. Rational design of E. coli for increased CoQ10 biosynthesis 
2.1 Introduction 
Previous studies, summarized in Chapter 1, have shown that the production of 
CoQ10 is feasible in E. coli. However, despite its great potential as a production host, the 
CoQ10 content currently obtained in engineered E. coli still falls below those obtained in 
mutant strains of R. radiobacter and R. sphaeroides (Table 1.1, Table 1.2) (Ha et al., 
2009; Yoshida et al., 1998; Zahiri et al., 2006b). Strategies used to improve CoQ10 
content in E. coli range from increasing the biosynthesis of isoprenoid precursors, to 
supplementation of aromatic intermediates, or over-expressing individual enzymes of the 
ubiquinone pathway. These studies, although unsuccessful in increasing CoQ10 
production levels above those of natural producers, offer hints into the factors limiting the 
production of this antioxidant in E. coli.
Several microbes are capable of CoQ10 biosynthesis, some of them in naturally 
high concentration. Their poor amenability to growth in the laboratory and to genetic 
modifications excludes them as hosts for industrial production. However, I may harness 
some of their inherent qualities by heterologously expressing selected genetic loci in the 
chosen host, E. coli. Ocean Nutrition Canada, a company using marine microbes and 
microscopic algae for the production of nutraceuticals, was our partner during initial 
stages of this project. They have collected and characterized a collection of marine 
microbes capable of CoQ10 production, which were made available as source of genetic 
material.  As mentioned in section 1.9.1, DPS enzymes are known to have relaxed 
product specificity, resulting in the production of ubiquinone species of varying length. A 
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first objective was therefore to identify an organism where CoQ10 is the only quinone 
species produced, which presupposes a DPS with strict product specificity. A second 
hypothesis was that a PHB prenyltransferase derived from a natural high CoQ10 producer 
would be more apt to convert high concentrations of substrates into ubiquinone 
intermediates. Previous literature has also shown that overexpression of UbiA is 
sufficient to increase CoQ10 production (Zhang et al., 2007). I attempted to express a
foreign UbiA in E. coli, derived from the high CoQ10 producer Erythrobacter sp. NAP1, 
and evaluated the resulting impact on CoQ10 production. 
It has been demonstrated that the effect of deregulated isoprenoid production on 
CoQ10 is potentiated by an exogenous supply of the aromatic precursor, PHB (Zahiri et 
al., 2006b). However, as no transporter for this organic acid has been characterized to 
date in E. coli, it is unclear to what extent exogenous PHB can be actively brought into E. 
coli cells. Moreover, the addition of PHB is impractical in the context of an industrial 
microbial platform. To ensure unrestricted supply of this molecule to the first enzyme of 
the ubiquinone pathway, the PHB prenyltransferase UbiA, I propose to increase the 
endogenous production of PHB. Elevated production of PHB from glucose has been 
achieved in E. coli  (Barker and Frost, 2001). The strategy employed was to over-express 
E. coli’s tktA, coding for a tranketolase, aroFFBR, coding for a feedback-insensitive 
isozyme of 3-deoxy-arabino-heptulosonate synthase, aroB, coding for a dehydroquinate 
synthase, aroL, coding for a shikimate synthase, aroA, coding for a 5-
enolpyruvylshikimate  3-phosphate synthase, aroC, coding for a chorismate synthase, and 
ubiC, coding for a chorismate lyase. Maximum yields of PHB were obtained using a 
strain defective in aromatic amino acid biosynthesis, in order to reduce enzymatic 
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competition with UbiC for chorismate. However, the resulting strain required 
supplementation of the culture medium with aromatic amino acids, and suffered cytotoxic 
effects associated with high concentrations of organic acid. In the context of a CoQ10 
production strain, achieving such high titers of PHB is not necessarily desirable. The 
combined effects of PHB toxicity and metabolic burden associated with multiple plasmid 
expression may prevent cell growth and optimal production of CoQ10. Alternatively, I 
aimed at engineering moderate but sustained PHB production in E. coli, which could be 
temporally coupled with the production of isoprenoid precursors. 
As the synthesis of one mole of CoQ10 requires ten moles of the isoprenoid 
building blocks, IPP/DMAPP, it is expected that flux through the isoprenoid pathway is 
to become rapidly restrictive in a CoQ10 production strain. Accordingly, increased 
CoQ10 production has been reported in strains overexpressing enzymes of the MEP 
pathway, or of a foreign mevalonate pathway (Choi et al., 2009; Kim et al., 2006; Zahiri 
et al., 2006b).  The latter strategy has an added advantage over the endogenous MEP 
pathway in that it bypasses native regulatory mechanisms that may make up-regulation 
for overproduction more problematic (Martin et al., 2003). For IPP/DMAPP and FPP 
synthesis, I used the pMevT and pMBIS plasmids developed as part of the initial 
demonstration that the mevalonate pathway may be expressed in E. coli for the 
production of amorphadiene (Martin et al., 2003).  The plasmid pMevT contains the 
“top” mevalonate operon, formed by atoB (E. coli), coding for an acetoacetyl-CoA 
thiolase, HMGS (S. cerevisiae), coding for 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA) synthase, and tHMGR (S. cerevisiae), coding for a truncated HMG-CoA reductase 
(HMGR). The top operon results in the conversion of acetyl-CoA to mevalonate (Figure 
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2.1). The plasmid pMBIS encodes the “bottom” mevalonate operon, allowing the 
conversion of mevalonate to DMAPP/IPP and FPP. This operon contains ERG12 (S.
cerevisiae), coding for a mevalonate kinase, ERG8 (S. cerevisiae), coding for a 
phosphomevalonate kinase, MVD1 (S. cerevisiae), coding for a mevalonate 
pyrophosphate decarboxylase, idi (E. coli), coding for an IPP isomerase, and ispA (E. 
coli), coding for a FPP synthase. Both parts of the pathway may be co-expressed, 
enabling the formation of isoprenoids from acetyl-CoA. Alternatively, one may express 
the lower part of the pathway alone and supplement cultures with exogenous mevalonate 
to enable the production of IPP/DMAPP and FPP. The expression of the top mevalonate 
operon, in the version present on pMevT, is associated with growth defects, due to an 
imbalanced pathway leading to the accumulation of a toxic intermediate, HMG-CoA 
(Pitera et al., 2007). I therefore chose to develop initial CoQ10 production strains with 
the bottom mevalonate pathway alone. Further along in this project, I obtained plasmids 
containing upgraded version of the top mevalonate pathway and was able to use them in 
my CoQ10 production strains. 
In this chapter, I report on the stepwise construction of a CoQ10 production strain 
where endogenous restrictions in precursor production are bypassed, and where flux 
through the ubiquinone pathway is augmented by the overexpression of a PHB 
prenyltransferase (Figure 2.1). Using this approach, I sought to identify bottlenecks 
limiting the accumulation of CoQ10 in this host. I report that the deregulated, over-
production of both aromatic and isoprenoid precursors of CoQ10 results in the 
accumulation of 2-decaprenylphenol, and that the production of this intermediate is 
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modulated by the expression of UbiA, as well as by the flux through the isoprenoid 
pathway.  
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A. Endogenous and foreign biosynthetic pathways engineered for the production of CoQ10 
in E. coli. Enzymes in black are endogenous to E. coli. Enzymes in grey are non-native or 
modified. Abbreviations; E4P, erythrose-4-phosphate; PEP, phosphoenolpyruvate; DAHP, 
3-deoxy-arabino-heptulosonate 7-phosphate; EPSP, 5-enolpyruvyl-shikimate-3-phosphate; 
PHB, para-hydroxybenzoate; GAP, glyceraldehyde-3-phosphate, DXP, 1-deoxy-D-
xylulose-5-phosphate; HMB-PP, 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate; HMG-
CoA, 3-hydroxy-3-methylglutaryl-CoA; DMAPP, demethylallyl diphosphate; IPP, 
isopentenyl diphosphate; FPP, farnesyl diphosphate; DPP, decaprenyl diphosphate; 10P-
HB, 3-decaprenyl-4-hydrobenzoate; 10P-Ph, 2-decaprenylphenol; 10P-HPh, 2-decaprenyl-
6-hydroxyphenol; 10P-MPh, 2-decaprenyl-6-methoxyphenol; 10P-MBQ, 2-octaprenyl-6-
methoxy-1,4-benzoquinol; 10P-MMBQ, 2-octaprenyl-3-methyl-6-methoxy-1,4-
benzoquinol; 10-MHMBQ, 2-octaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinol; 
CoQ10H2, ubiquinol-10; CoQ10, coenzyme Q10. B. Synthetic operons used in this study. 
pTDPSo contains dpso, coding for a decaprenyl diphosphate synthase, and driven by the trc
promoter. pTUbiAoDPSo, and pTUbiAeDPSo contains ubiAo or ubiA, respectively, coding 
for a PHB decaprenyl transferase, and dpso, driven by the trc promoter. pJUbiI contains 
ubiI driven by lacZp. pALTAA and aroB::LTAA (integrated downstream of aroB on the 
chromosome) contain tktA, coding for transketolase, aroFFBR, coding for a tyrosine-
insensitive 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase, and aroB, coding for a
3-dehydroquinate synthase, driven by lacZp. ubiC::LLACC contains aroL, coding for a
shikimate kinase, aroA, coding for a 5-enolpyruvyl-shikimate-3-phosphate synthase, aroC,
coding for a chorismate synthase, and ubiC, coding for and a chorismate lyase, driven by 
lacZp and integrated downstream of ubiC on the chromosome. pMBIS contains ERG12,
coding for a mevalonate kinase, ERG8, coding for a phosphomevalonate kinase, MVD1,
coding for a mevalonate pyrophosphate decarboxylase, idi, coding for an IPP isomerase, 
and ispA, coding for a FPP synthase, driven by lacZp. pMtSa contains atoB, coding for a 
acetyl-CoA acetyltransferase, ERG13, coding for a 3-hydroxy-3-methylglutaryl-CoA  
synthase and SaHMGR, coding for a 3-hydroxy-3-methylglutaryl-CoA reductase, driven by 
lacZp.  
2.2 Materials and methods 
2.2.1 Reagents, strains and culture conditions 
E. coli strains and plasmids used in this chapter are listed in Table 2.1. E. coli
DH5α was used for cloning whereas CoQ10-producing strains were constructed in E. coli
MG1655. E. coli strains containing the individual gene knockouts ΔaroK::kan,
ΔaroL::kan, ΔaroA::kan and ΔaroC::kan were obtained from the Keio collection (Baba 
et al., 2006). When required, strains were propagated on Luria Bertani (LB) medium 
(Sambrook et al., 1989) supplemented with 100 μg/mL ampicillin, 20 μg/mL 
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chloramphenicol, 12.5 μg/mL tetracycline, and/or 25 μg/mL kanamycin. Polymerase 
chain reactions (PCR) for cloning purposes were performed with Phusion High-Fidelity 
DNA Polymerase (New England Biolabs) while colony PCR reactions to identify 
positive clones were conducted using Taq DNA polymerase (Fermentas). DNA isolated 
from agarose gels and PCR reactions were purified using the QIAquick Gel and 
QIAquick PCR purification kit (Qiagen), respectively. Plasmid extractions were done 
using the GeneJET Plasmid Miniprep Kit (Fermentas). All plasmids used or constructed 
in Chapter 2 are described in Table 2.1. Sequences for all primers used in Chapter 2 are 
reported in Table 2.2. Chemicals were obtained from Sigma-Aldrich. Mevalonate was 
prepared by mixing 1 volume of 2 M D,L-mevalolactone to 1.02 volumes of 2 M KOH 
and incubating for 30 minutes at 37°C, as previously described (Martin et al., 2003). 
Growth experiments presented in sections 2.3.1 to 2.3.5 were performed in M9 medium 
(Sambrook et al., 1989) supplemented with 1.5% yeast extract, 3% glucose and 
appropriate antibiotics at ½ concentration, in order to reduce the initial lag phase. Optical 
densities were converted to DCW using a standard curve, which determined a conversion 
factor of 1 OD600= 0.37 g/L DCW. Experiments presented in sections 2.3.6 to 2.3.8 were 
done in M9 medium supplemented with 3% glucose and antibiotics at full concentration. 
To prepare starter cultures for testing the engineered strains, one colony was used to 
inoculate a 10-mL culture, which was grown overnight and adjusted to OD600=1.  The 
starter cultures were then diluted ten-fold in 50 mL of medium in 250-mL shake flasks 
and shaken at 200 revolutions per minute (rpm) and 37°C. When the cultures reached an 
OD600 of 0.5-0.7, they were supplemented with 10 mM mevalonate as necessary and 0.5 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG), unless noted otherwise.
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Table 2.1 Strains and plasmids used in Chapter 2 
Strain Genotype / description Reference
DH5α
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 
endA1 thi-1 hsdR17 Invitrogen







CC001 MG1655 + pTDPSo This study
CC002 MG1655, ΔispB + pTDPSo This study
CC003 MG1655 + pALac This study
CC004 MG1655 + pALTAA This study
CC005 MG1655, ΔaroK, ΔaroL + pALac This study
CC006 MG1655, ΔaroK, ΔaroL + pALTAA This study
CC007 MG1655, ubiC::LLACC + pALac This study
CC008 MG1655, ubiC::LLACC + pALTAA This study
CC009 MG1655, ΔispB + pTDPSo + pALac + pBBR1MCS3 This study
CC010 MG1655, ΔispB + pTDPSo + pALac + pMBIS This study
CC011 MG1655, ΔispB, ubiC::LLACC + pTDPSo + pALTAA + pBBR1MCS3 This study
CC012 MG1655, ΔispB, ubiC::LLACC + pTDPSo + pALTAA + pMBIS This study
CC013 MG1655, ΔispB + pTUbiAoDPSo + pALac + pBBR1MCS3 This study
CC014 MG1655, ΔispB + pTUbiAoDPSo + pALac + pMBIS This study
CC015 MG1655, ΔispB, ubiC::LLACC + pTUbiAoDPSo + pALTAA + pBBR1MCS3 This study
CC016 MG1655, ΔispB, ubiC::LLACC + pTUbiAoDPSo + pALTAA + pMBIS This study
CC017 MG1655, ΔispB, ubiC::LLACC + pTDPSo + pALTAA + pMBIS + pJUbiI This study
CC018 MG1655, ΔispB, ubiC::LLACC + pTDPSo + pALTAA + pMBIS + pJPK12 This study
CC019
MG1655, ΔispB, ubiC::LLACC, aroB::LTAA + pTUbiAeDPSo  + pMBIS + 
pMtSa This study
CC020
MG1655, ΔispB, ubiC::LLACC, aroB::LTAA + pTUbiAeDPSo  + pMBIS + 
pMtDa This study
CC021 MG1655, ΔispB + pTUbiAoDPSo This study
CC022 MG1655, ΔispB + pTUbiAeDPSo This study
CC023
MG1655, ΔispB, ubiC::LLACC, aroB::LTAA + pTUbiAeDPSo  + pMBIS + 
pMtSa This study
Plasmid Description Reference
pACYC184 Low-copy expression plasmid; TetR, CmR ATCC 37033
pALac pACYC184 derivative containing the lacZ promoter; CmR This study
pALDPSo pALac derivative containing DPSo; CmR This study
pTrc99A High-copy expression plasmid; AmpR Pharmacia
pTDPSo pTrc99A derivative containing DPSo; AmpR This study
pTUbiANDPS
pTrc99A derivative containing ubiAN (Erythrobacter sp. NAP1) and DPS;
AmpR This study
pTUbiAEDPS pTrc99A derivative containing ubiA (E. coli) and DPS; AmpR This study
pTUbiAoDPSo pTrc99A derivative containing ubiAo and DPSo; AmpR This study
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pGEM-T Easy High-copy cloning plasmid; AmpR Promega
pG-TktA pGEM-T Easy derivative containing tktA; AmpR This study
pG-AroF pGEM-T Easy derivative containing aroF; AmpR This study
pG-AroFFBR pGEM-T Easy derivative containing aroFFBR; AmpR This study
pG-AroB pGEM-T Easy derivative containing aroB; AmpR This study
pGFPuv High-copy plasmid containing lacZp-GFPuv; AmpR ClonTech
pUC19 High-copy cloning plasmid; AmpR Fermentas
pUSERGFP pUC19 derivative containing a USER cloning cassette and GFPuv; AmpR This study
pUTAAG pUSERGFP derivative containing tktA, aroFFBR and aroB; AmpR This study
pALTAA pALac derivative containing tktA, aroFFBR and aroB; CmR This study
pALLACC pALac derivative containing aroL, aroA, aroC and ubiC; CmR This study
pLOI2224
plasmif with the RK6γ origin containing a KanR cassette and two FRT sites, 
for chromosomal integration of DNA; kanR
(Martinez-
Morales et al., 
1999)
pBBR1MCS3 Low-copy expression plasmid; TetR
(Kovach et 
al., 1995)
pMBIS pBBR1MCS3 derivative containing ERG12, ERG8, MVD1, idi and ispA; TetR
(Martin et al., 
2003)




pJUbiI pJPK12 derivative containing ubiI; KanR This study
pTUbiAeDPSo pTrc99A derivative containing ubiAo and DPSo; AmpR This study
pMtSa pBAD33 derivative containing atoB, HMGS, SaHMGR; CmR
(Ma et al., 
2011)
pMtDa pBAD33 derivative containing atoB, HMGS, DaHMGR; CmR
(Ma et al., 
2011)
Table 2.2 Oligonucleotides used in Chapter 2  




























































Primer name 5' to 3' sequence
VisC-BHI-F AGCTGGATCCACCGAGGAGGAAAAATTATGCAAAGTGTTGATGTAGCCATTG
VisC-Nt-R AGGTGCGGCCGCTTAACGCAGCCATTCAGGCAAATCGTTTAATC
2.2.2 P1 phage transduction of deleted loci and inserted operons 
Multiple gene knockouts and insertions in E. coli MG1655 were generated by P1 
transduction (Thomason et al., 2007). To generate phage lysate from a donor strain,  the 
latter was grown in 5 mL LB medium supplemented with 5 mM CaCl2 and 0.2% glucose 
to OD600=0.2, at which point 100 μL of P1 phage lysate (from E. coli MG1655) was 
added. The culture was shaken at 37°C and 200 rpm for 3 hours, until cell lysis. Lysate 
was transferred into 1.5 mL tubes to which was added 25 μL chloroform, vortexed for 30 
seconds, then spun down at 16,000 x g for 1 minute. The supernatant was transferred in a 
new 1.5 mL tube with 15 μL chloroform and kept at 4°C. For the transduction of donor 
DNA into a recipient strain, the latter was grown in 5 mL LB supplemented with 5 mM 
CaCl2 and 0.2% glucose to OD600=0.8. Cells were then concentrated 4 times into LB 
supplemented with 5 mM CaCl2 and 100 mM MgSO4. A 1/10 dilution of donor phage 
lysate in the same medium was also prepared. In a 1.5 mL tube, 100 μL of recipient cells 
were mixed to 100 μL of diluted phage and incubated at 37°C for 30 minutes. The phage 
transduction process was then stopped by adding 200 μL 1M sodium citrate (pH=5.5). 
One mL of LB was added and cells were incubated at 200 rpm and 37°C for one hour, 
then plated on LB supplemented with 25 μg/mL kanamycin. Positive transductants were 
confirmed by colony PCR. 
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2.2.3  Construction of cloning and expression vectors 
pALac: The pALac expression vector is derived from the low-copy plasmid 
pACYC184. The vector was amplified using the primers pACYC184F and pACYC184R 
(Table S1), which anneal to regions flanking the tetracycline resistance cassette, and 
carry 5’-NsiI and NotI sites (pACYC184F) or 5’-NsiI and AscI sites (pACYC184R). The 
PCR product was digested with NsiI and DpnI and self-ligated, yielding pACCM.  lacZp 
was amplified from E. coli MG1655 by colony PCR using the primers lacPAscIF and 
LacPPme1R1, and then with the primers LacPPMIBHI-R2 and LacPNotIR3. The lacZp 
cassette was then introduced into pACCM using the AscI and the NotI sites, yielding 
pALac. 
pG-USER-GFP: In order to create a cloning vector to assemble the upper 
aromatic operon by the USER method (Geu-Flores et al., 2007), I created a module 
flanked by FseI, SbfI, NotI and SacI sites at the 5’ end, and by AscI and XbaI at the 3’ 
end, containing a PacI/NtBbvCI cassette, a ribosomal binding site and the coding 
sequence of GFP. This module was created by PCR using the primer pair USER-GFP-
F1/USER-GFP-R1 and pGFPuv as a template. The primer pairs USER-GFP-F2/USER-
GFP-R2, USER-GFP-F3/ USER-GFP-R3, and USER-GFP-F4/USER-GFP-R3 were then 
used in sequential overlapping PCR reactions. The cassette was digested with SacI and 
XbaI and inserted into pUC19, yielding pUSER-GFP. 
2.2.4 Isolation of the dps gene from Sphingomonas baekryungensis  
Sphingomonas baekryungensis was isolated from seawater in Advocate Bay 
(Nova Scotia, Canada) and identified as a high producer of CoQ10 (patent 
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WO2008023264: Coenzyme Q10 production from marine bacteria). To isolate the dps
gene from S. baekryungensis, degenerate PCR primers (DPSF6 and DPSR4) were first 
designed based on the conserved DPS amino acid regions LLHDDV and AFQLVD (Lee 
et al., 2004). A 384-bp PCR fragment was amplified from S. baekryungensis genomic 
DNA, cloned into pGEM-T Easy (Promega), and sequenced. To generate the template for 
inverse PCR and isolate the 5’ and 3’ regions of the dps gene, genomic DNA from S. 
baekryungensis was digested with NcoI, and the purified fragments were self-ligated. 
This template was used to amplify a 2.5-kb fragment containing the 5’ and 3’ ends of the 
S. baekryungensis dps gene, using primers DPS-iPCR-F1 and DPS-iPC-R1, designed 
based on the 384-bp dpsS.bae internal fragment. The entire coding sequence of dpsS.bae was 
then amplified using the primers DPSF1 and DPSR1. A synthetic version of the dpsS.bae
gene was codon-optimized for E. coli by GeneScript, yielding dpso. The synthetic gene 
was amplified using the primers RBSDPSoKpnIF and DPSoHindIIIR, adding an 
optimized RBS (Ringquist et al., 1992) at the 5’ end, and cloned into pTrc99A, yielding 
pTDPSo (Figure 1B). The dpso gene was also amplified with the primers 
RBSDPSBamHIF and DPSNotIR, introducing an optimized RBS at the 5’ end, then
cloned into pALac, yielding pALDPSo.  
2.2.5  Deletion of ispB from E. coli 
To minimize the production of CoQ8, the ispB gene was deleted from the 
chromosome of E. coli using lambda Red recombination (Datsenko and Wanner, 2000). 
A 1597-bp deletion cassette was amplified using primers IspBkoF and IspBkoR, and the 
plasmid pKD4 as a template. The reactions were treated with DpnI, and dialyzed using a 
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0.025 μm disc (Millipore). Cells of E. coli BW25113 harboring pKD46 and pALDPSo
that were previously grown on LB containing L-arabinose (1 mM), were electroporated 
using ~475 ng of the purified DNA cassette. The ∆ispB::kan locus was transferred to 
MG1655 harboring pTDPSo by P1 transduction. The kanamycin marker flanked by FRT 
sites was removed using the helper plasmid pCP20, as previously described (Datsenko 
and Wanner, 2000).  
2.2.6 Isolation of the ubiA gene from Erythrobacter sp. NAP1 
The amino acid sequence of the PHB decaprenyl transferase (UbiA) from 
Erythrobacter sp. NAP1 was retrieved from GenBank (EAQ29552.1). The corresponding 
coding sequence was codon-optimized for E. coli and synthesized by DNA2.0, yielding 
ubiAo. The optimized gene and an optimized ribosomal binding site (Ringquist et al., 
1992) were inserted into pTDPSo using EcoRI and KpnI, upstream of dpso, yielding 
pTUbiAoDPSo (Figure 1B).   
2.2.7 Construction of the synthetic aromatic pathway operons 
The coding regions of tktA, aroF and aroB were amplified from MG1655 
genomic DNA using the primer pairs TktAF1/TktAR1, AroFF2/AroFR2 and 
AroBF2/AroBR2, respectively, then cloned into pGEM-T Easy, yielding pG-TktA, pG-
AroF and pG-AroB. The primers AroF-PL-F1 and AroF-PL-R1 were used to introduce 
the base pair modification (C444T) required to introduce Pro (148) ?Leu mutation in 
AroFFBR (Weaver and Herrmann, 1990). The resulting pG-AroFFBR was further modified 
by site-directed mutagenesis using the primers AroF-T327C-F and AroF-T327C-R, in 
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order to remove a PacI recognition site. For USER cloning (Geu-Flores et al., 2007), tktA
was amplified using PfuTurbo Cx hotstart DNA polymerase (Agilent Technologies) from 
pG-TktA using the primers TktAUF1/TktAUR1, aroFFBR from pG-AroFFBR with the 
primers AroFUF2/AroFUR2, and aroB from pG-AroB with the primers 
AroBUF4/AroBUR4. The fragments were DpnI-treated, purified and mixed with 
pUSER-GFP pre-digested with PacI and Nt.BbvCI, as well as one unit of USER enzyme.
After 20 minutes at 37°C and 20 minutes at 25°C, the whole reaction was transformed 
into E. coli, yielding plasmid pUTAAG. The tktA-aroFFBR-aroB operon was amplified 
from pUTAAG using the primers TktAF2 and AroBR3, and then cloned into pALac,
yielding pALTAA (Figure 1B). The coding regions of aroL, aroA, aroC and ubiC were 
amplified from MG1655 genomic DNA using the primer pairs AroLF/AroLR, 
AroAF/AroAR, AroCF/AroCR and UbiCF/UbiCR, respectively. The operon was built by 
iterative digestion, ligation, and amplification of the ligated coding regions. Briefly, the 
amplified coding region of aroL was digested with AvrII at the 3’ end while the amplified 
coding region of aroA was digested with XbaI at the 5’ end. The two digested products 
were then ligated, which destroyed both the AvrII and XbaI sites, and subsequently 
amplified with AroLF and AroAR. The same procedure was repeated for the addition of 
the amplified aroC and ubiC to the operon. Once the entire operon was constructed, it 
was digested with BglII and NotI and then cloned into BamHI-NotI-digested pALac, 
yielding pALLACC. 
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2.2.8 Construction of pJUbiI 
The open reading frame of the ubiI locus was amplified from the chromosome of 
E. coli by colony PCR, using primers VisC-BHI-F and VisC-Nt-R, adding a BamHI site 
and a NotI site at the 5’ and 3’ end, respectively. The PCR product was purified, then 
digested with BamHI and NotI and cloned into the plasmid pALac, downstream of the 
lacZ promoter. After the identity of the coding sequence was verified by Sanger 
sequencing, the lacZp:ubiI cassette was excised using HindIII/NotI and inserted into the 
low-copy expression vector, pJPK12, yielding pJUbiI. 
2.2.9  Integration of the synthetic aromatic operons on the chromosome of E. coli 
The LacZp:tktA-aroFFBR-aroB and the LacZp:aroL-aroA-aroC-ubiC  operons 
were integrated on the chromosome of E. coli at the aroB and ubiC loci, respectively, by 
homologous recombination using the method of Martinez-Morales (1999). A GFP 
cassette flanked by NotI and AscI sites was first cloned at the NotI site of pALTAA and 
pALLACC, and allowed the excision of AscI-flanked fragments. Each operon was cloned 
into the AscI site of pLOI2224, yielding p24LTAA and p24LLACC. The plasmid 
p24LTAA was subsequently electroporated into MG1655 ΔtktA, ΔaroF, and p24LLACC 
into MG1655 ΔaroL, ΔaroA, ΔaroC, yielding aroB::LTAA-kan and ubiC::LLACC-kan.
The ubiC::LLACC-kan locus was transferred into MG1655, and the kanamycin cassette 
excised using pCP20, yielding MG1655 ubiC::LLACC. The aroB::LTAA-kan locus was 
transferred into MG1655 ubiC::LLACC by P1 transduction, and the kanamycin cassette 
excised using pCP20, yielding MG1655 ubiC::LLACC, aroB::LTAA. 
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2.2.10 Analysis of shikimic acid and PHB from culture supernatants 
For HPLC analysis of shikimic acid and PHB from culture supernatants, one-mL 
aliquots from E. coli cultures were centrifuged at 16,100 x g to remove the cells. The 
supernatant was filtered using a 13 mm 0.2 μM nylon filter (Acrodisc, VWR), and 10 μL 
was injected into a 1200 Series HPLC system (Agilent technologies) equipped with an 
Aminex HPX-87H column (Bio-Rad) heated to 65°C. Shikimic acid was resolved using 
0.1% trifluoroacetic acid at a flow rate of 0.6 mL/minute and detected with a 1200 Series 
UV/Vis diode array detector (Agilent Technologies) at 215 nm. PHB was resolved using 
0.1% trifluoroacetic acid and 15% acetonitrile at a flow rate of 0.6 mL/minute and 
detected at 254 nm. Shikimic acid and PHB were quantified using standard curves of 
authentic standards. 
2.2.11 Quinone extraction and analysis 
To analyze cellular quinone content, cells from one-mL aliquots of E. coli 
cultures were harvested at 16,100 x g prior to quinone extraction. The pelleted cells were 
washed with 1 mL of 50 mM Tris-HCl pH 7.5, and re-suspended in 450 μL Cell Lytic B 
(Sigma-Aldrich). After 30 minutes at room temperature, a first extraction was performed 
with 900 μL of hexane:2-propanol (5:3). The upper phase was transferred into a new tube 
and a second extraction was done using 500 μL of hexane. The combined extracts were 
dried under an air stream, and re-suspended in 50 μL acetone. A 10-μL aliquot was 
injected into a 1200 Series HPLC system equipped with a ZORBAX Eclipse XDB-C18 
(4.6 x 150 mm, 5 μm, Agilent technologies). The mobile phase consisted of acetonitrile 
(A) and ethanol (B), ran at 0.5 mL/minute with the following elution profile: 0-5 minutes, 
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40% B; 5-18 minutes, 40%-100% B; 18-32 minutes, 100% B. The quinones were 
detected at 275 nm. CoQ10 was quantified using a standard curve of an authentic 
standard. For identification by LC-MS-MS, the extracted quinones were separated by 
HPLC as described above, except that the mobile phase was acidified with 0.1% formic 
acid and 10 μM ammonium formate. The HPLC eluent was then channeled to a Quattro 
LC triple quadrupole mass spectrometer (Waters) with electrospray ionization in the 
positive mode. The source block temperature was set to 80 °C, the disolvation 
temperature to 200 °C, and a voltage of 3.5 kV was applied to the electrospray needle. 
Nitrogen was used as the nebulizer, disolvation, and collision gas. The precursor ions 
were manually selected and directed to the collision cell where they were fragmented 
with 30 kV or 40kV of collision energy, depending on the metabolite. The identity of 
10P-Ph was confirmed by LC-MS-MS on a LTQ Orbitrap Velos MS (Thermo Electron). 
The mass spectrometer was equipped with a heated-electrospray ionization source, which 
was operated in positive ion mode with a source voltage of 3.0 kV and a capillary 
temperature of 380 °C, and the spectra were recorded at a normalized collision energy of 
25 with pulsed-Q dissociation. 
2.3 Results 
2.3.1 Cloning and functional expression of a dps in E. coli 
Ocean Nutrition Canada has established a vast collection of marine microbes, 
isolated from sea water, sediments and sea weeds collected from Advocate Bay, Nova 
Scotia. The marine bacterium S. baekryungensis was identified in a screen for high 
producers of CoQ10. Analysis of its quinone profile also revealed negligible amounts of 
44
shorter quinone species such as CoQ9 (Figure 2.2). Since previous studies have shown 
that the chain length of CoQn species is dictated by the polyprenyl synthase (Okada et al., 
1996), I hypothesized that the DPS expressed by this species had higher stringency for 
DPP compared to other CoQ10 producers who also produce shorter coenzyme species 
(Okada et al., 1998; Park et al., 2005; Takahashi et al., 2003; Zahiri et al., 2006a).  
Figure 2.2 Screen of marine bacteria for high CoQ10 content.  
Strain ONC-Q0010 was identified as Sphingomonas baekryungensis. Data graciously 
provided by Ocean Nutrition Canada. 
In order to engineer a strain highly enriched in CoQ10, I isolated the open-reading 
frame of a putative dps (dpsS.bae) from S. baekryungensis. As detailed in section 2.2.4, this 
was done using degenerate primers designed to anneal the coding sequence of a highly 
conserved motif characterizing long-chain prenyl diphosphate synthases. The amino acid 
sequence of DPSS.bae was deducted and aligned with previously characterized DPS 
proteins. This revealed that the putative DPSS.bae shared several conserved domains with 
other DPS’s. Amino acids at the 8th, 5th and 4th position before the first aspartate-rich 
motif (FARM) determine the chain length of the product of the prenyl disphosphate 
Biomass (g/L) CoQ9 (mg/g DCW) CoQ10 (mg/g DCW)
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synthase (Wang and Ohnuma, 2000). Enzymes that make short products, such as 
geranylgeranyl diphosphate synthases have large amino acids, while enzymes that make 
longer products (C30-C50) contain short amino acids at these positions, such as alanine, 
threonine and isoleucine, which were found in DPSS.bae and conserved in DPS enzymes 
of other species (Figure 2.3).  
Figure 2.3 Multiple alignment of DPS proteins from S. baekryungensis and other 
representative microbial species 
The amino acid sequence the DPSS.bae from S. baekryungensis was deducted from the 
sequenced open-reading frame. The amino acid sequences of the other DPS proteins were 
obtained from GenBank. The alignment was done using Clustal W2. Stars indicate 
conserved residues among all species. The conserved FARM motifs are framed. The 
arrows indicate the 4th, 5th and 8th residues preceding the first FARM motif.  
G. oxydans -----------------------------------------------MLACNRAIIARME 13
R. sphaeroides --------------------------MGLDEVSQKPHERLAAWLAEDMAAVNGLIRERMA 34
R. radiobacter MPHKASVFIVEFKFELESCPLGVVIPLEESKNKLASVKPLVDLTRPDMERVNQLILSKAG 60
S. baekryungensis ------------------MSDNVVPIKRGPDASPPTLTPILTLTATPMNSVNSIILDRMQ 42
*   *  *  :  
G. oxydans S-PVPLIPQLGAHLVAAGGKRLRPLLTLASARLCGYQPGPDHQRHVGLAACVEFIHTATL 72
R. sphaeroides SKHAPRIPEVTAHLVEAGGKRLRPLLTLAAARLCGYEG----PYHIHLAATVEFIHTATL 90
R. radiobacter S-DVQMIPEVANHLISSGGKRLRPMLTLASASMFGYEG----DNHIKLATSVEFMHTATL 115
S. baekryungensis S-EIPLIPALAGHLIAGGGKRMRPMLTLAGAQVVGYQG----TRHHKLAAAVEFIHTATL 97
*     ** :  **: .****:**:****.* : **:       *  **: ***:*****
G. oxydans LHDDVVDESTLRRGLASANAVFGNKASVLVGDFLFARSFQLMTADGSLKVMAILSDASAT 132
R. sphaeroides LHDDVVDESHRRRGKPTANLLWDNKSSVLVGDYLFARSFQLMVETGSLRVMDILANASAT 150
R. radiobacter LHDDVVDESDLRRGKSTARTIWGNQASVLVGDFLLGQAFRMMVDVGSLDALDVLSTAASV 175
S. baekryungensis  LHDDVVDGSEMRRGKSAANIVYGNPATVLVGDFLFSRAFELMVEDGSLKVLKILSGASAI 157
*:***** *  *** .:*. ::.* ::*****:*:.::*.:*.  *** .: :*: *:: 
G. oxydans IAEGEVLQMVVQNDLTTPVERYLEVIHGKTAALFAAACRVGAVVAERPEAEEEALERFGT 192
R. Sphaeroides ISEGEVLQLTAAQDLRTTEDIYLQVVRGKTAALFAAATEVGGVVAGVPEAQVEALHAYGD 210
R. radiobacter IAEGEVLQLSVAKNMETTEDDYLQVIRAKTAALFAAAAEVGPIVAKTDKATRSALKSYGM 235
S. baekryungensis  IAQGEVDQLTAQRKIETSEERYLTIIGAKTAALFAAASRISAVVAEKSEEEEMALDSYGR 217
*::*** *: . ..: *. : ** :: .********* .:. :**   :    **. :* 
G. oxydans NLGMAFQLVDDALDYAADQQVLGKTVGDDMREGKITLPVLAAYEAGSPEDRIFWERVIGE 252
R. Sphaeroides ALGIAFQIVDDLLDYGGVDAQIGKNTGDDFRERKLTLPVIKAVAQADAEERAFWQRVIEK 270
R. radiobacter NLGLAFQLVDDVLDYGGKSADLGKNTGDDFREGKITLPVILSYRRGTQDERAFWRTAIEK 295
S. baekryungensis  NLGIAFQLVDDAIDYDSEAAEMGKDRGDDFREGKMTLPVILAYARGNEEERRFWQDAIAG 277
**:***:*** :** .    :**  ***:** *:****: :   .  ::* **. .*  
G. oxydans GEQTEDDLPHALNLIAKTGAINTTIARAQVYADAAVEALSIFPDSELRRLLIETVQFTVN 312
R. Sphaeroides GDQREGDLEQAHAIMSRHGAMEAARQDALRWVTVAREALGQLPEHPLREMLHDLADFVVE 330
R. radiobacter GESSDENLEKALGLITKYNGLGDTIGRATHYGTIARDALAPLPQSPWKDALLEVIDFCIE 355
S. baekryungensis  FSTEDEDLAHAVDLIRKHDCVTATRERARHYAQRACDALSIFPDSAARRAMVEAAQFAVA 337
.  : :* :*  :: : . :  :   *  :   * :**. :*:   :  : :  :* : 
G. oxydans RAR 315
R. Sphaeroides RIA 333
R. radiobacter RLN 358
S. baekryungensis  RGY 340
*
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The nucleotide sequence of DPSS.bae was codon-optimized (dpso) in order to 
improve expression and the activity of DPSo was confirmed by the accumulation of 
CoQ10, in addition to CoQ8, in E. coli MG1655 transformed with pTDPSo (Figure 2.4B, 
strain CC001).  In order to exclusively produce CoQ10, the ispB gene was deleted and 
complemented by dpso, yielding CC002. When comparing the quinone profile of the 
?ispB strain CC002 with that of a control strain (MG1655 + pTrc99A), I observed that 
while the control exclusively produced octaprenyl quinones (CoQ8 and menaquinone-8),
CC002 produced the decaprenyl quinones CoQ10 and menaquinone-10, as well as longer 
CoQ11 (Figure 2.4B and C). Although some CoQ9 was found in cells expressing both 
ispB and dpso (strain CC001, Figure 2.4B), I did not observe detectable amounts of CoQ9 
in CC002 (Figure 2.4C).
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Figure 2.4 Quinone profile and identification from recombinant E. coli strains 
A) HPLC chromatogram of extracted quinones from MG1655+pTrc99A, CC001 and 
CC002. Labelled peaks were identified by LC-MS-MS, and are shown in B) Peak 1: MS-
MS spectrum of CoQ8, ammonium adduct [M+NH4]+ (C49H78O4N+; exact mass 744.6), 
protonated adduct [M+H]+ (C49H75O4+; exact mass 727.7), and tropylium ion [M]+
(C10H13O4+, exact mass 197.1). Peak 2: MS-MS spectrum of CoQ9, ammonium adduct 
[M+NH4]+ (C54H85O4N+; exact mass 812.6), protonated adduct [M+H]+ (C54H83O4+; exact 
mass 795.6), and tropylium ion [M]+ (C10H13O4+, exact mass 197.1). Peak 3: MS-MS 
spectrum of menaquinone-8, ammonium adduct [M+NH4]+ (C51H76O2N+; exact mass 
734.6), protonated adduct [M+H]+ (C51H73O2+; exact mass 717.6), and tropylium ion [M]+
(C12H11O2+, exact mass 187.1). Peak 4: MS-MS spectrum of CoQ10, ammonium adduct 
[M+NH4]+ (C59H94O4N+; exact mass 880.7), protonated adduct [M+H]+ (C59H91O4+; exact 
mass 863.7), and tropylium ion [M]+ (C10H13O4+, exact mass 197.1). Peak 5: MS-MS 
spectrum of CoQ11, ammonium adduct [M+NH4]+ (C64H102O4N+; exact mass 948.7), 
protonated adduct [M+H]+ (C64H99O4+; exact mass 931.7), and tropylium ion [M]+
(C10H13O4+, exact mass 197.1). Peak 6: MS-MS spectrum of menaquinone-10, ammonium 






































adduct [M+NH4]+ (C61H92O2N+; exact mass 870.7), protonated adduct [M+H]+ (C61H89O2+;
exact mass 853.7), and tropylium ion [M]+ (C12H11O2+, exact mass 187.1). 
2.3.2 Deregulation of PHB biosynthesis 
The benzoic head of CoQ10 is derived from the shikimate pathway leading to the 
biosynthesis of chorismate, which is then converted to PHB by the chorismate lyase, 
UbiC (Figure 2.1A). The overexpression of the rate-limiting enzymes of the shikimate 
pathway, along with UbiC, allows for the production of high PHB titers in E. coli (Barker 
and Frost, 2001). Based on this strategy, I created two synthetic operons, referred to as 
the upper and lower aromatic operons, aimed at increasing the expression of selected 
genes coding for enzymes of the PHB pathway (Figure 2.1B). 
The upper aromatic operon, designed to increase the production of shikimate, 
comprises the genes coding for TktA, a feedback resistant AroF (AroFFBR), and AroB,
driven by the lacZ promoter (Figure 2.1B). AroFFBR is a mutated version of AroF, made 
insensitive to feedback inhibition by tyrosine via a single proline-to-leucine modification 
(Weaver and Herrmann, 1990). I tested the functionality of the upper aromatic operon by 
following the accumulation of shikimic acid over time in MG1655 harboring pALTAA 
(CC004).  Strain CC004 secreted 0.7 mM of shikimic acid (Figure 2.5A). To prevent the 
rapid conversion of shikimate to downstream aromatic intermediates, and get a better 
estimate of shikimate production, I expressed pALTAA in E. coli MG1655 ∆aroK∆aroL,
a strain deficient in shikimate kinase activity, yielding CC006. Using this genetic 
background, the production of shikimate increased 21-fold compared to the control 
CC005 (MG1655 ∆aroK∆aroL, pALac) and 2.5-fold compared to CC006, leading to the 
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excretion of 1.7mM shikimic acid (Figure 2.4A). The expression of the upper operon 
alone in CC004 resulted in the accumulation of 0.05 mM of PHB (Figure 2.5C).
The lower aromatic operon (LACC) includes the genes coding for AroL, AroA, 
AroC, and UbiC. The expression of these four enzymes leads to the conversion of 
shikimate to PHB (Figure 2.1A). The lower operon was placed under the control of 
lacZp, and integrated on the chromosome downstream of the ubiC locus (ubiC::LLACC, 
Figure 2.1B) of CC003 and CC004, yielding CC007 and CC008, respectively. I did not 
observe an increase in PHB productivity in CC007, expressing solely the lower aromatic 
operon, indicating that availability of shikimate is limiting for PHB biosynthesis (Figure 
2.5C). However, CC008, expressing both upper and the lower operons, produced over 0.4 
mM of PHB, representing a 220-fold increase compared to the control CC003 , and a 
25% yield from shikimate (Figure 2.5C). No residual shikimate was detected in the media 
of CC008, suggesting that the fraction of shikimate that was not converted to PHB was 
channeled to other aromatic molecules.   
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Figure 2.5 Production of aromatic intermediates following the expression of the upper 
and lower synthetic aromatic pathway operons
Tested strains were grown to exponential phase, and induced with 0.5 mM IPTG. Samples 
were taken at 0, 4, 24, and 96 hours after induction. Strains CC003, CC004, CC005 and 
CC006 were compared for A) secretion of shikimic acid in the growth medium B) optical 
density. Strains CC003, CC004, CC007 and CC008 were compared for C) secretion of 
PHB in the growth medium D) optical density. Error bars show the standard deviation for 
two biological replicates. 
2.3.3  Assessment of CoQ10 production following the overexpression of PHB and/or 
FPP biosynthetic pathways 
As the availability of PHB limits the carbon flux toward ubiquinone biosynthesis 
(Zahiri et al., 2006b; Zhu et al., 1995), I hypothesized that a deregulation of PHB 
biosynthesis would translate into higher production of CoQ10 in an engineered E. coli 
strain. The upper and lower aromatic operons were introduced into the CoQ10-producing 
strain CC002, yielding CC011, and CoQ10 production was followed over time. Strain 











































































a control in order to determine basal production levels of CoQ10, when the biosynthesis 
of precursors is endogenously regulated. As shown in Figure 2.6A, CC011 produced up 
to 0.24 mg/g DCW of CoQ10, corresponding to a 1.3-fold increase compared to the 
control CC009. In addition, CC011 produced 0.09 mM of PHB (Figure 2.6C), a four-fold 
decrease compared to CC008 (Figure 2.5C).  
In addition to aromatic precursors, the biosynthesis of CoQ10 in recombinant E. 
coli is limited by the availability of DPP for the prenylation of PHB (Choi et al., 2009; 
Kim et al., 2006; Zahiri et al., 2006b). DPP is formed by the successive condensation of 
IPP with FPP (Wang and Ohnuma, 2000). In E. coli, the biosynthesis of these isoprenoid 
molecules can be dramatically increased by the heterologous expression in E. coli of the 
typically eukaryotic mevalonate pathway  (Martin et al., 2003). The pMBIS plasmid 
harbors the lower mevalonate operon, which enables the conversion of mevalonate into 
IPP, DMAPP and FPP (Figure 2.1A, B). The expression of pMBIS results in significant 
increases in the production of FPP and IPP in the presence of exogenously supplied 
mevalonate (Martin et al., 2003). In order to increase the availability of FPP for CoQ10 
biosynthesis, I transformed pMBIS into CC002, yielding CC010. The expression of the 
lower mevalonate pathway in CC010 resulted in a 2-fold increase in CoQ10 content (0.33 
mg/g DCW) over the control CC09 (Figure 2.6A).  
I then hypothesized that an even greater increase in CoQ10 production would be 
observed if both the PHB and the isoprenoid pathways were over-expressed in the same 
strain. The engineered aromatic and lower mevalonate pathways were introduced in strain 
CC002, resulting in strain CC012, and the latter was tested for CoQ10 production. As 
shown by Figure 2.6C, CC012 reached a CoQ10 content of 0.43 mg/g DCW, a 2.6-fold 
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increase over the control CC009. This demonstrates that both aromatic and isoprenoid 
precursors are rate-limiting for CoQ10 biosynthesis and that both of these pathways can 
be simultaneously engineered in E. coli to produce high CoQ10-producing strain without 
the need for feeding the PHB precursor. Only a slight difference was observed in PHB 
accumulation between CC012 and CC011 (Figure 2.5B).  
Figure 2.6 Production of CoQ10 and PHB in strains expressing the synthetic aromatic 
operons and/or the bottom mevalonate operon.
Strains CC009 (diamonds), CC010 (triangles), CC011 (squares) and CC012 (circles) were 
grown for five days. Cultures were induced during exponential phase with 0.5 mM IPTG 
and 10 mM mevalonate. Samples were taken at 0, 4, 24, 72 and 120 hours after induction 
in order to measure A) CoQ10 production B) optical density C) extracellular PHB. Error 
bars represent the standard deviation of two biological replicates. 
In addition to its increased CoQ10 content, CC012 had elevated concentrations of 






















































chromatogram (Figure 2.7A). Analysis of this unknown compound by LC-MS-MS
revealed a precursor ion at m/z=792.7828 and a product ion at m/z=107.0493 (Figure 
2.7C), characteristic of the ammonium adduct [M+NH4]+ and the tropylium ion [M]+,
respectively, derived from the CoQ10 intermediate, 2-decaprenylphenol (10P-Ph) (Cox et 
al., 1969; Hsu et al., 1996; Matsumura et al., 1983). 10P-Ph is the second intermediate of 
the ubiquinone pathway, formed by the hydroxylation of 3-decaprenyl-4-
hydroxybenzoate (10P-HB) (Figure 2.1A) (Alexander and Young, 1978). Although the 
lack of an analytical standard precluded the quantification of this compound, a 
comparison of its relative abundance between different strains revealed that CC012 
accumulated 14 times more 10P-Ph than CC010, while CC011 and CC009 did not 
accumulate detectable levels of this intermediate (Figure 2.7B).  
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Figure 2.7 Identification and accumulation pattern of 10-Ph following the expression 
of the synthetic aromatic operons and of the bottom mevalonate operon.
The production of a ubiquinone pathway intermediate, 10P-Ph, was characterized. A)
HPLC chromatogram of extracted quinones from CC012, 24 hours after induction with 0.5 
mM IPTG and 10 mM mevalonate. The 10P-Ph peak is labelled with a star. B) Time-
course of 10P-Ph production in strains CC009 (diamonds), CC010 (triangles), CC011 
(squares) and CC012 (circles). Error bars represent the standard deviation of two biological 
replicates C) LC-MS-MS spectrum of 10P-Ph. The most abundant product ions identified 
from the MS-MS are illustrated below the spectra. In particular, the fragmented precursor 
ion yielded an ammonium adduct [M+NH4]+ (C56H90ON+, exact mass 792.7022) and a
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2.3.4  Overexpression of a PHB decaprenyltransferase from Erythrobacter sp. NAP1 
Although I observed an increase in CoQ10 production following the 
overexpression of both the aromatic and the lower mevalonate pathways in CC012, I 
found that PHB accumulation levels by the latter and by CC011 were almost similar 
(Figure 2.6C). The entry of PHB and DPP into the ubiquinone pathway is catalyzed by 
the PHB prenyltransferase, UbiA, condensing DPP to PHB to form 10P-HB (Figure 
2.1A). It is possible that the limited flux of PHB towards the ubiquinone pathway in 
CC012 reflects a bottleneck at the PHB prenylation step carried out by UbiA. I 
hypothesized that microorganisms naturally accumulating high levels of CoQ10 might 
express PHB prenyltransferases of increased efficiency. Preliminary experiments showed 
that expression of the PHB prenyltransferase from Erythrobacter sp. NAP1 (via 
pTUbiANDPS) restored growth defects associated with the production of high levels of 
IPP/DMAPP and FPP (via pMBIS), suggesting that this orthologue of UbiA was capable 
of pulling toxic isoprenoid intermediates down the ubiquinone pathway more efficiently 
than E. coli’s UbiA (via pTUbiAeDPS) (Figure 2.8).  
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Figure 2.8 Effect of PHB prenyltransferase variants on growth of E. coli strains 
harboring pMBIS. 
The following strains were grown in replicate (N=6) in a 96-well plate incubated in a 
microtiter plate reader with continuous shaking: MG1655, pTrc99A, pBBR1MCS3 (grey 
squares); MG1655, ptrc99A, pMBIS (white triangles); MG1655, pTUbiANDPS,
pBBR1MCS3 (grey circles); MG1655, pTUbiAeDPS, pBBR1MCS3 (grey diamonds);
MG1655, pTUbiANDPS, pMBIS (white circles); MG1655, pTUbiAeDPS, pMBIS (white 
diamonds). After one hour, triplicate cultures of each strain were induced with A) 0.5 mM 
IPTG or B) 0.5 mM IPTG and 10 mM mevalonate, as indicated by the arrow. Optical 
densities were measured automatically by the plate reader. Values show the average of 
triplicates. Data graciously provided by A. Ekins. 
In order to overcome a potential bottleneck at the PHB prenylation step in my
engineered E. coli strains, I expressed a codon-optimized version of ubiA (ubiAo) that was 
isolated from the CoQ10-producing marine bacterium Erythrobacter sp. NAP1 (Figure 
2.1B). The plasmid pTUbiAoDPSo was expressed in a ∆ispB background along with 
empty vectors (CC013), the bottom mevalonate pathway (CC014), the aromatic operons 
(CC015), or both the bottom mevalonate and aromatic operons (CC016) (Table 2.1).
The heterologous expression of ubiAo in CC013, CC014, CC015, and CC016 was 
associated with an extended initial lag phase and with reduced growth (Figure 2.9B). 
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2.9D). However, taking into consideration lower cell density in CC016 cultures, PHB 
secretion was in fact comparable between the two strains, with 0.04 mmol/g DCW PHB 
produced by CC016 and 0.05 mmol/g DCW by CC012.  Consistent with the hypothesis 
that the overexpression of UbiAo favors the production of CoQ10 when high 
concentrations of aromatic and isoprenoid precursors are available, CC016 achieved the 
highest CoQ10 content amongst the strains tested. As shown by Figure 2.9A, CC016 
produced up to 0.58 mg/g DCW of CoQ10, compared to 0.37 mg/g DCW for CC012 
(Figure 2.9A). In contrast to its higher CoQ10 content, CC016 produced 2.8-fold less 
10P-Ph than CC012 (Figure 2.9C). This suggests that the overexpression of UbiAo
reduces the accumulation of 10P-Ph in CC016, and favors the accumulation of CoQ10.  
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Figure 2.9 Time-course of CoQ10, 10P-Ph and PHB production following the 
expression of the aromatic operons, the bottom mevalonate operon and/or the PHB 
prenyltransferase UbiAo
Strains CC012 (empty circles), CC013 (filled diamonds), CC014 (filled triangles), CC015 
(filled squares) and CC016 (filled circles) were grown for five days. Cultures were induced 
during early exponential phase with 0.5 mM IPTG and 10 mM mevalonate. Samples were 
taken at 0, 3, 25, 72 and 120 hours after induction in order to measure A) CoQ10 
production B) optical density C) 10P-Ph production D) extracellular PHB. Error bars 
represent the standard deviation of two biological replicates. 
The overexpression of UbiAo along with the lower mevalonate pathway in CC014 
resulted in the accumulation of a new compound, which eluted from the HPLC column 
4.5 minutes before CoQ10 (Figure 2.10A). Analysis of this molecule by LC-MS-MS
revealed a precursor ion of m/z 818 and a product ion of m/z 150, corresponding to the 
protonated precursor ion and to the tropylium product ion, respectively, of 3-decaprenyl-
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2010). The accumulation of this hybrid metabolite had never been observed in a CoQ10-
producing E. coli strain, but had been reported in E. coli when UbiA uses para-
aminobenzoate (PABA) as its substrate, typically when the production of PHB is 
defective (Hamilton and Cox, 1971; Lawrence et al., 1974). Interestingly, none of the 
other strains tested produced measurable amounts of 10P-AB (Figure 2.10C). 
Figure 2.10 Identification and accumulation pattern of 10P-AB in a strain 
overexpressing a PHB prenyl transferase and the bottom mevalonate pathway 
The production 10P-AB was characterized in CC014. A) HPLC chromatogram of extracted 
quinones from CC014, 24 hours after induction with 0.5 mM IPTG and 10 mM 
mevalonate. The 10P-AB peak is labeled with a star. B) LC-MS-MS spectrum of 10P-AB. 
The fragmented precursor ion yielded a protonated ion [M+H]+ (C57H88NO2+, exact mass 
818.7), and a tropylium ion [M]+ (C8H8NO2+, exact mass 150.1). C) Time-course of 10P-
AB production in stains CC012 (empty circles), CC013 (filled diamonds), CC014 (filled 
triangles), CC015 (filled squares) and CC016 (filled circles), after induction with 0.5 mM 
IPTG and 10 mM mevalonate. Error bars represent the standard deviation of two biological 
replicates. 
2.3.5 Overexpression of a putative monooxygenase of the ubiquinone pathway, UbiI 
The accumulation of 10P-Ph reported in sections 2.3.3 and 2.3.4 highlights the 
existence of a bottleneck in the ubiquinone pathway, preventing the conversion of 10P-Ph 
to the downstream intermediate, 2-decaprenyl-6-hydroxyphenol (Figure 2.1A). The 
overexpression of UbiAo partially relieved this bottleneck, but CoQ10 synthesis in my












































in the form of 10P-Ph. To address this problem, the open-reading frame of ubiI, coding 
for the putative monooxygenase responsible for the hydroxylation of 10P-Ph (Hajj 
Chehade et al., 2013), was placed under the control of a lacZ promoter and plasmid-
localized. The resulting construct, pJUbiI, was expressed in strain CC012, yielding strain 
CC017. The corresponding empty plasmid, pJPK12, was also transformed into CC012, 
yielding the control strain CC018. I deliberately chose not perform initial tests in strains 
expressing UbiAo because of the growth defects associated with this heterologous 
enzyme, and the potential additional burden associated with the expression of a fourth 
plasmid, pJUbiI.  
The expression of pJUbiI had no significant effect on CoQ10 production and on 
10P-Ph accumulation in strain CC017 (Figure 2.11). Consequently, UbiI was not over-
expressed in subsequent experiments. 
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Figure 2.11 CoQ10 and 10P-Ph production following the expression of pJUbiI 
Strain CC017 and CC018 were induced with 0.5 mM IPTG and 10 mM mevalonate during 
early exponential phase, and grown for five days. CoQ10 (grey bars) and 10P-Ph (white 
bars) were extracted at the end of fermentation. Error bars show the standard deviation of 
two biological replicates. 
2.3.6 Expression of the complete mevalonate pathway 
The CoQ10 production strains engineered so far expressed the bottom mevalonate 
pathway, enabling the conversion of exogenously supplied mevalonate into the 
isoprenoid building blocks, IPP, DMAPP and FPP (Martin et al., 2003). Biosynthesis of 
mevalonate from acetyl-CoA in E. coli is possible using the plasmid pMevT, bearing the 
top mevalonate operon, which contains the genes atoB, HMGS and tHMGR (Martin et al., 
2003). However, the expression of this plasmid is associated with growth defects in E. 
coli, due to an imbalance in the pathway leading to the accumulation of the toxic 
intermediate, HMG-CoA (Pitera et al., 2007). For this reason, I initially chose to avoid its 
expression in my CoQ10 production strains. Over the last few years, considerable 
research has focused on the optimization of the top mevalonate pathway, and new 
plasmids variants allowing more streamlined conversion of acetyl-CoA to mevalonate 
have been constructed (Anthony et al., 2009; Ma et al., 2011; Pitera et al., 2007). I have 
obtained two of such variants, pMtSa and pMtDa (Ma et al., 2011). In these vectors, the 



































aureus (SaHMGR) or by a HMGR from Delphia acidovorus (DaHMGR), respectively. 
The plasmids pMtSa and pMtDa contain a chloroamphenicol resistance marker, as does 
the plasmid pALTAA. Therefore, in order to obtain strains expressing the full mevalonate 
pathway, I transferred the top aromatic operon, lacZp:tktA-aroFFBR-aroB, on the 
chromosome of E. coli, downstream of the aroB locus. The resulting strains, MG1655 
∆ispB, pTDPSo, ubiC::LLACC, aroB::LTAA, pMBIS, pMtSa (CC019) and MG1655 
∆ispB, pTDPSo, ubiC::LLACC, aroB::LTAA, pMBIS, pMtDa (CC020), were tested for 
CoQ10 production (Table 2.1). As shown by Figure 2.12, the expression of pMtSa in 
CC019 resulted in higher CoQ10 titers compared to CC020 (pMtDa) and CC012. The 
ratio of 10P-Ph to CoQ10 was also smaller in this strain, indicating the expression of 
pMtSa favored higher flux through ubiquinone pathway.  
Figure 2.12 CoQ10 and 10P-Ph production following the expression of two variants of 
the top mevalonate operon.  
Cultures of CC019 (pMtSa) , CC020 (pMtDa) and CC012 were induced with 0.5 mM 
IPTG and 10 mM mevalonate (CC012 only) during exponential phase. After five days 
fermentation, CoQ10 (grey bars) and 10P-Ph (white bars) were quantified. Values 
represent the average of two quinone extractions. 
2.3.7 Expression of a PHB prenyltransferase from E. coli, UbiA 
As reported in section 2.3.4, the expression of ubiAo, the synthetic gene derived 









































deleterious effects on cell growth. I had originally concluded, from preliminary 
experiments, that replacing ubiAo by E. coli’s native PHB prenyltransferase, ubiA, would 
not alter this growth phenotype. However, I later revisited these results and was prompted 
to further investigate differences between ubiAo or ubiA overexpression. I replaced ubiAo
on the expression plasmid pTubiAoDPSo by the open reading frame of E. coli’s native 
PHB prenyltransferase, ubiA. The new plasmid was used to complement ΔispB, and the 
resulting strain, ΔispB pTubiAeDPSo (CC022), was compared to strains ΔispB
pTubiAoDPSo (CC021) and ΔispB pTDPSo (CC002). I found that without IPTG 
induction, the growth pattern of CC021 and CC022 were comparable, both strains 
reaching lower densities than strain CC002 (Figure 2.13A). However, while the induction 
of the operon resulted in 29% reduction of growth in CC021, it had no noticeable effect 
on CC022 (Figure 2.13A). Furthermore, I found that CoQ10 production was higher 
following the expression of UbiA (CC022) than of UbiAo (CC021) (Figure 2.13B). Based 
on these findings, the plasmid pTubiAeDPSo was used to build a new CoQ10 production 
strain, MG1655 ∆ispB, pTubiAeDPSo, ubiC::LLACC, aroB::LTAA, pMBIS, pMtSa
(strain CC023, Table 2.1). 
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Figure 2.13 Growth and CoQ10 production following the expression of different PHB 
prenyltransferases 
A) Strains CC002, CC021 and CC022 were grown in replicate (N=6) in a 96-well plate 
incubated in a microtiter plate reader with continuous shaking. Triplicate cultures of each 
strain were induced with 0.5 mM IPTG after two hours. Optical densities were measured 
automatically by the plate reader. Values show the average of triplicates. B) Strains 
CC002, CC021 and CC022 were grown for 48 hours and CoQ10 measured. Values show 
the average of duplicate extractions. 
2.3.8 Effect of IPTG induction on CoQ10 production 
The choice of the lacZ and trc promoters to drive the expression of synthetic 
operons was based on the premise that expression would remain low until an inducer 
(IPTG) was added to the culture. However, the leakiness of such promoters is well 
documented and IPTG can be omitted without undermining product accumulation 
following the expression of heterologous genes (Anthony et al., 2004; Zahiri et al., 
2006b). As strain CC023 does not require the addition of mevalonate during early 
exponential phase, I was prompted to question the requirement for IPTG addition. I 
compared CoQ10 production following induction of CC023 with increasing 
concentrations of IPTG. As shown by Figure 2.14, IPTG induction had minimal effects 
on CoQ10 production. Moreover, the omission of IPTG diminished the synthesis of 10P-



































































for the construction of the CoQ10 production strains are leaky and allow minimal control 
over the timing of expression of the synthetic operons. The addition of IPTG was 
henceforth omitted in subsequent experiments.  
Figure 2.14 Effect of IPTG on CoQ10, CoQ11 and 10P-Ph accumulation 
Strain CC023 was grown for five days. Different IPTG concentrations were added during 
early exponential phase. Error bars show the standard deviation of three biological 
replicates. 
2.4 Discussion 
The use of E. coli as a host for the production of CoQ10 offers several 
advantages, including a range of genetic tools allowing deletion and insertion of selected 
loci, the expression of foreign genes, and the capacity to alter metabolic pathways to 
increase the availability of precursors. As a first part in this thesis, I sought to 
systematically investigate how different approaches, both hypothesized and published, 
affect the flux of carbon towards CoQ10 in recombinant E. coli  (Zahiri et al., 2006b; 
Zhang et al., 2007). As such, I set out to enhance flux of precursor molecules to the 
ubiquinone pathway by simultaneously increasing the production of both aromatic and 
















































genetic material, by overexpressing a DPS derived from S. baekryungensis and a PHB 
prenyltransferase from Erythrobacter sp. NAP1.  
2.4.1 Overexpression of the aromatic pathway 
In order to ensure the availability of increased levels of PHB in situ, rate-limiting 
enzymes of the shikimate pathway, along with UbiC, were over-expressed in a CoQ10-
producing E. coli strain (Figure 2.1) (Barker and Frost, 2001). The expression of a first 
operon deregulated the conversion of E4P and PEP to shikimate, while enzymes encoded 
by a second operon ensured higher flux from shikimate to PHB.  Expression of these two 
operons, upon IPTG induction, led to the accumulation of up to 0.43 mM of PHB when 
the synthetic aromatic operons were expressed alone (Figure 2.5C), and 0.08 mM of PHB 
when the mevalonate pathway and DPSo were co-expressed. The additional burden 
brought by the maintenance of two additional plasmids, the expression of additional 
heterologous proteins, as well as the conversion of PHB to CoQ10 and ubiquinone 
intermediates, may account for this discrepancy. Although far from the yields previously 
obtained (Barker and Frost, 2001), the production of 0.08 mM of PHB corresponds to a 
40-fold increase from the control strain CC009, and could yield up to 16 mg/g DCW of 
CoQ10. 
2.4.2 Overexpression of a heterologous mevalonate pathway 
Expression of the mevalonate pathway aimed at alleviating bottlenecks resulting 
from the rate-liming supply of isoprenoid precursors (Kim et al., 2006; Zahiri et al., 
2006b). Increased production of FPP and IPP/DMAPP alone, resulting from the 
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expression of the bottom mevalonate pathway, augmented by 2-fold the CoQ10 content 
of CC010 (Figure 2.6A, Figure 2.9A).  Expression of the top mevalonate pathway, 
through pMtDa or pMtSa, further enhanced CoQ10 production. Inadequate activity of the 
enzyme HMGR has bacteriostatic effects, due to the toxicity of HMG-CoA (Pitera et al., 
2007). The pMtSa and pMtDa plasmids contain variant HMGRs, SaHMGR (S. aureus) 
and DaHGMR (D. acidovorus), respectively, mediating the conversion of HMG-CoA to 
mevalonate. SaHMG is NADPH-dependent, while DaHGMR is NADH-dependent (Ma 
et al., 2011). Close links exists between redox homeostasis and ubiquinone’s functions
and biosynthetic pathway (Bekker et al., 2007; Georgellis et al., 2001; Huang et al., 
2011). Therefore, both plasmids were tested in the context of CoQ10 production. The 
expression of the NADPH-dependent SaHMGR favoured CoQ10 production over that of 
DaHMGR (Figure 2.12). These results may be due to differences in redox status between 
the two strains, or to kinetic properties of S. aureus HMGR, which favor higher
mevalonate production than D. acidovorans HMGR during aerobic growth (Ma et al., 
2011). 
2.4.3 Heterologous expression of a decaprenyl diphosphate synthase 
The increased flux of precursors towards the ubiquinone pathway substantially 
improved CoQ10 production in engineered E. coli. However, the 1 mg/g DCW of CoQ10 
obtained in CC023 is lower than what was previously obtained (Zahiri et al., 2006b), and 
represents a fraction of the expected yield from PHB and isoprenoids in my strain, 
indicating that bottlenecks still prohibit maximum CoQ10 content. Despite the expression 
of the mevalonate pathway in strain CC023, the amount of isoprenoid committed to 
68
CoQ10 biosynthesis might be limited by the activity of DPSo, which may not fully 
convert FPP and IPP/DMAPP into DPP. I have shown that complementation of the ΔispB
deletion strain, an essential gene for E. coli (Okada et al., 1997b), with dpso is sufficient 
to restore growth. However, assuming similar extinction coefficients between CoQ8 and 
CoQ10, the accumulation of CoQ10 in strain CC002 is less than the accumulation of 
CoQ8 in the wild-type strain MG1655 (Figure 2.2). This suggests that either catalytic 
properties of DPSo are inferior to those of IspB, or that DPSo is not adequately expressed. 
DPSo activity also leads to the production of CoQ11, suggesting that this particular 
enzyme produces undecaprenyl diphosphate in addition to DPP. While the heterologous 
expression of several DPS proteins has been documented to result in the production of 
shorter polyprenyl species in addition to DPP, as inferred by the accumulation of a 
mixture of CoQ10, CoQ9 and CoQ8 (Okada et al., 1997a; Park et al., 2005; Takahashi et 
al., 2003; Zahiri et al., 2006a), the biosynthesis of undecaprenyl diphosphate and of 
CoQ11, has, to the best of my knowledge, never before been reported in E. coli.
Interestingly, no CoQ11 was detected from quinone extracts of S. baekryungensis 
(personal communication, Adam Burja). This suggests a loss of specificity occurring 
exclusively during heterologous expression. The addition of the inducer, IPTG, favors the 
accumulation of CoQ11, supporting the idea that loss of specificity is a side effect of the 
deregulated overexpression of DPSo. A more complete characterization and optimization 
of DPSo activity and expression, or an investigation into alternative DPS enzymes with 
variable kinetic properties (Ma et al., 2011), may be necessary to ensure that the supply 
of DPP is not limiting CoQ10 production. 
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2.4.4 Overexpression of a PHB prenyltransferase 
Supporting previous studies, the overexpression of a PHB prenyltransferase had a 
significant impact on CoQ10 production (Figure 2.9A) (Zhang et al., 2007). However, 
my results do not support the initial hypothesis that a PHB prenyltransferase derived from 
a high CoQ10 producer (Erythrobacter sp. NAP1) would have enhanced kinetic 
properties compared to the endogenous PHB prenyltransferase of E. coli. Moreover, the 
expression of ubiAo had cytotoxic effects on E. coli. It remains unclear why the 
replacement of ubiAo by ubiA (E. coli) was able to attenuate these effects. The codon-
optimization of UbiAo might have had a negative effect on its expression. Rare codons 
sometimes increase the overall translational efficiency and may influence protein folding, 
particularly in the case of membrane proteins (Norholm et al., 2012).  Increased 
production of isoprenoids coupled with the overexpression of UbiAo in CC014 led to the 
accumulation of a new metabolite, 10P-AB (Figure 2.10). This compound does not have 
a known biological function in E. coli, but accumulates in a mutant lacking chorismate 
lyase activity when grown in the presence of PABA (Hamilton and Cox, 1971). Growth 
inhibition of E. coli by high concentrations of exogenous PABA can be reversed by the 
addition PHB (Davis, 1951), suggesting that PABA may act as a competitive inhibitor of 
UbiA by displacing PHB within the active site of UbiA. In CC014, the increased PHB 
prenyltransferase (UbiAo) activity combined with the higher availability of DPP may 
result in the exhaustion of the endogenously produced PHB, causing UbiA/UbiAo to 
accept PABA as an alternative substrate. In S. cerevisiae, PABA can also be used as a
substrate for Coq2p and further channeled through the ubiquinone pathway (Marbois et 
al., 2010). Based on my results, it would appear that while UbiA can use PABA to form 
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10P-AB, the latter compound is not recognized by the E. coli decarboxylases UbiD and 
UbiX, therefore leading to an accumulation of this metabolite in CC014 (Figure 1.2).
These findings demonstrate the importance of precursor stoichiometry in metabolic 
engineering complex multi-branch pathways. 
2.4.5 Accumulation of 2-decaprenylphenol 
The enhanced production of aromatic and isoprenoid precursors in CC012 and 
CC016 led to the accumulation of 10P-Ph, an intermediate of the ubiquinone pathway 
(Figure 2.7B; Figure 2.9C). While the accumulation of 10P-Ph and 2-octaprenylphenol 
(8P-Ph) as a by-product of CoQ10 and CoQ8 biosynthesis has been documented in 
anaerobic cultures of P. denitrificans (Matsumura et al., 1983) and E. coli (Alexander and 
Young, 1978), respectively, this is the first time that the accumulation of 10P-Ph is
reported in an E. coli strain engineered to produce CoQ10. A recent study has identified 
UbiI as the monooxygenase converting 8P-Ph to 2-octaprenyl-6-hydroxyphenol (Hajj 
Chehade et al., 2013). However, an accumulation of 10P-Ph does not necessarily reflect 
insufficient UbiI expression, as E. coli strains bearing mutations in the ubiquinone 
pathway genes ubiB, ubiH, and ubiG all accumulate 8P-Ph (Young et al., 1973; 
Alexander and Young, 1978; Hsu et al., 1996; Poon et al., 2000). Accordingly, the 
overexpression of UbiI in strain CC017 did not reduce 10P-Ph accumulation nor lead to 
increase CoQ10 production (Figure 2.11). When flux through the ubiquinone pathway 
increases as a result of the augmented production of aromatic and isoprenoid precursors, 
the activity of one of the above-mentioned Ubi enzymes may become rate-limiting, 
resulting in the accumulation of 10P-Ph. Strain CC016, overexpressing UbiAo, had a 
71
lower 10P-Ph content compared to CC012, along with higher CoQ10 production (Figure 
2.9A,C), suggesting that increasing PHB prenyltransferase activity improves flux within 
the ubiquinone pathway, downstream of the decarboxylation step. It is possible that one 
or more enzymes of the ubiquinone pathway are dependent on UbiA for their activity. 
Studies in S. cerevisiae provide compelling evidence for the existence of a multi-protein 
complex involved in the production of CoQ6 (Gin and Clarke, 2005; Gin et al., 2003; 
Johnson et al., 2005; Tran et al., 2006). It is hypothesized that Coq2p, the homologue of 
UbiA, does not physically interact with the complex, but that its product, 3-hexaprenyl-4-
hydroxybenzoate, plays a role in the assembly and/or stability of the complex (Hsieh et 
al., 2007; Hsu et al., 2000; Suzuki et al., 1994).  As described in more detail in Chapter 1 
(section 1.5), physical interactions between Ubi proteins have not yet been demonstrated 
in E. coli, but early literature on the ubiquinone pathway hints at the existence of a 
soluble multi-protein complex capable of converting 8P-Ph to CoQ8 (Knoell, 1979; 
Knoell, 1981). The accumulation of 10P-Ph may reflect limitations in activity of stability 
of this putative complex.  The introduction of pMtSa into CoQ10 production strains and 
the omission of IPTG from the fermentation medium also diminished the 10P-Ph/CoQ10 
ratio, but these observations offer little insight on underlying mechanisms driving flux 
through the ubiquinone pathway. Moreover, as I was unable to quantify 10P-Ph, I cannot 
assert how much of the observed reduction in 10P-Ph accumulation translates into further 
CoQ10 biosynthesis. Further work focused on enzymes of the ubiquinone pathway will 
be key to completely eliminate the bottleneck resulting in 10P-Ph accumulation in CoQ10 
production strains.  
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In summary, this chapter describes the development of a CoQ10-producing E. coli 
strain engineered to overproduce aromatic and isoprenoid precursors and to have 
increased PHB prenyltransferase activity. It is the first instance where both precursor 
pathways have been overexpressed and genetically deregulated in combination with the 
overexpression a PHB prenyltransferase, the enzyme bridging these two pathways. The 
results presented in this chapter highlight the existence of previously unreported 
bottlenecks in CoQ10 overproduction in E. coli, and will enhance our ability to design 
further improvements of this system. The resulting strain, CC023, achieved a 5.8-fold 
increase in CoQ10 content compared to the control strain CC009, over-expressing DPSo
alone (Figure 2.14; Figure 2.6A), thereby demonstrating the effectiveness of the chosen 
approach. The maximum specific content obtained, 1 mg/g DCW of CoQ10, is inferior to 
those reported when isoprenoid production and/or UbiA and UbiC expression were 
enhanced (Huang et al., 2011; Zahiri et al., 2006b). However, these studies presented
CoQ10 yields obtained from engineered E. coli strains grown on rich, optimized growth 
media, which was beyond the scope of these initial experiments, and make comparisons 
difficult. The strain engineered in the first part of this thesis still requires optimization. In 
particular, a more extensive analysis of the accumulation patterns of intermediate 
metabolites will be required to ensure proper balancing of the pathway and optimal 
carbon flow. Nevertheless, this “base strain” had, at this point in my research, the 
potential to be used as tool to investigate the interplay between central metabolism and 
CoQ10 production, and to better understand inherent factors limiting the accumulation of 
this antioxidant in E. coli. The results of these investigations are presented in Chapter 3. 
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Chapter 3. Investigation into the interplay between central metabolism 
and CoQ10 production in an engineered strain of E. coli
3.1 Introduction 
Chapter 2 describes the stepwise construction of a CoQ10-producing strain of E.
coli. I showed that a simultaneous increase in the production of isoprenoid and aromatic 
precursors was beneficial to CoQ10 production, in particular when the expression of a 
PHB prenyltransferase was concurrently increased. I next wished to explore different 
strategies to further enhance CoQ10 production, with a special focus on central 
metabolism. Review of the literature pertaining to ubiquinone biosynthesis in microbes 
offers several hints that the production of this antioxidant is linked to the cell’s primary 
metabolism. In particular, ubiquinone synthesis appears to have closed ties with 
catabolism, oxidative respiration as well as redox homeostasis.  
CoQ10 production in R. radiobacter is upregulated on selected carbon sources 
(Ha et al., 2007b; Koo et al., 2010). In addition, the expression of a number of ubiquinone 
biosynthetic genes of E. coli, including ubiA, ubiC, ubiG, ubiD and ubiX, is higher on 
non-fermentable carbon sources compared to glucose, suggesting catabolite repression as 
a means of control (Gibert et al., 1988; Kwon et al., 2005; Zhang and Javor, 2003). The 
nature of the carbon substrate is also expected to have an impact on fluxes through the 
engineered precursor pathways. For instance, substrate import via a phosphotransferase 
system may decrease the availability of PEP as a building block in the synthesis of the 
aromatic intermediate, PHB (Patnaik and Liao, 1994). Accordingly, I investigated an 
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array of carbon sources representative of the different ways in which catabolism may 
exert influence on CoQ10 production.   
As a major player in E. coli’s aerobic respiration, it is expected that ubiquinone 
biosynthesis is linked to the cell’s respiratory state. Expression of ubiC, ubiA and ubiG is 
lower under anaerobic conditions, indicating transcriptional control of ubiquinone 
biosynthesis in response to respiratory state (Gibert et al., 1988; Kwon et al., 2005; 
Soballe and Poole, 1997). There is also evidence for post-transcriptional control over the 
ubiquinone to menaquinone ratio, upon a switch from anaerobic to aerobic conditions 
(Shestopalov et al., 1997). Interestingly, although aerobic respiration requires ubiquinone 
for electron transport, limiting the O2 supply to growing cultures increases CoQ10 
production in R. radiobacter and R. sphaeroides (Choi et al., 2005; Ha et al., 2007b; 
Sakato et al., 1992; Yoshida et al., 1998). As detailed in Chapter 1 (section 1.10), these 
observations, along with respiration inhibitors studies, suggest that cells may compensate 
restricted flux of electron through the respiratory chain by upregulating the biosynthesis 
of ubiquinone (Bekker et al., 2007; Choi et al., 2005). Overall, endogenous mechanisms 
controlling ubiquinone synthesis appear intricate and many fold. Under this premise, I 
chose to introduce genetic alterations in the electron transport chain of the engineered E. 
coli, as a mean to mimic restrictions in electron flux susceptible to trigger upregulation of 
CoQ10 production. 
Both catabolism and oxidative respiration are closely linked to redox homeostasis, 
which is mainly driven by the ratios NADH/NAD+ and NADPH/NADP+. Manipulating 
the ratio of pyridine nucleotides for metabolic engineering purposes in E. coli is an 
effective strategy (Lin et al., 2005; Nikel et al., 2010). Nevertheless, these manipulations 
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may result in significant changes in metabolic partitioning, adding unforeseen complexity 
to the engineered system. For instance, when the NAD+-dependent glyceraldehyde-3-
phosphate dehydrogenase, GapA, was replaced with the NADP+-dependent 
glyceraldehyde-3-phosphate dehydrogenase, GapC, from C. acetobutylicum, to increase 
the availability of NADPH in E. coli, there was a downregulation of the pentose-
phosphate pathway, normally the major source of NAPDH in cells (Martinez et al., 
2008). In the case of CoQ10 production, the down-regulation of the pentose-phosphate 
pathway would be detrimental, as it is essential for the production of aromatic precursors 
leading to PHB (Figure 3.1). In R. radiobacter, there is a positive correlation between the 
NADH/NAD+ ratio and the resulting CoQ10 content (Koo et al., 2010). It is possible that 
higher NADH/NAD+ ratio results in increased activity of the electron transport chain, 
which re-oxidizes NADH through the activity of NADH-dehydrogenases. Overall, little 
is known about the impact of redox homeostasis on CoQ10 production in E. coli, but the 
biological function of ubiquinone as an electron acceptor and the anecdotal evidence 
from R. radiobacter studies highlight the potential of this approach.
In this Chapter, I investigated the effect of different carbon sources on CoQ10 
production in the base strain, CC023, as well as the impact of selected mutations, altering 
oxidative respiration or mixed-fermentation pathways. I found a link between sorbitol 
metabolism and CoQ10 production in the engineered strain, CC023. I also demonstrated 
that abrogating the production of acetate in the same strain can partly mimic the results 
obtained on sorbitol. My experiments were hindered by reproducibility and stability 
issues in all strains expressing the synthetic aromatic and mevalonate pathways. This has 
prevented a more thorough investigation regarding the link between acetate, sorbitol and 
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CoQ10 production. Nevertheless, the results presented in this Chapter suggest novel 
directions to engineer further improvements in CoQ10 production in E. coli. 
Figure 3.1 Central metabolism and engineered CoQ10 production in E. coli 
Summary of the main reactions in E. coli’s central metabolism and oxidative respiration.
ATP, adenosine triphosphate; ADP, adenosine diphosphate; NADH, nicotinamide adenine 
dinucleotide; NADPH, nicotinamide adenine dinucleotide phosphate. G3P, glycerol-3-
phosphate; DHAP, dihydroxyacetone phosphate; GAP, glyceraldehyde-3-phosphate; 1,3-
BPG, glycerate 1,3-bisphosphate; 3PG, 3-phospho-glycerate; 2PG, 2-phospho-glycerate;
PEP, phosphoenolpyruvate; PYR, pyruvate; acetyl-P, acetyl phosphate; isocit, isocitrate; α-

































































































































































hydroxy-3-methylglutaryl-CoA;  Mev 5-P, 5-phosphomevalonate; Mev2P, mevalonate 
pyrophosphate; IPP, isopentenyl diphosphate; DMAPP, dimethylallyl diphosphate; FPP, 
farnesyl diphosphate; DPP, decaprenyl diphosphate; X5P, xylulose 5-phosphate;  R5P, 
ribose 5-phosphate; S7P, sedo-heptulose-7-phosphate; F6P, fructose 6-phosphate; E4P, 
erythrose-4-phosphate; DAHP, 3-deoxy-arabino-heptulosonate 7-phosphate; DHQ, 3-
dehydroquinate; DHS, 3-dehydroshikimate; S3P, shikimate 3-phosphate; EPSP, 5-
enolpyruvyl-shikimate 3-phosphate; PHB, para-hydroxybenzoate; CoQ10H2, ubiquinol; 
CoQ10, coenzyme Q10. 
3.2 Materials and methods 
3.2.1 Strains and reagents and culture conditions 
The strains of E. coli, and the plasmids used in this chapter are listed in Table 3.1. 
Plasmid construction and propagation was done using E. coli DH5-α. The strains 
developed for the production of CoQ10 are derived from MG1655. E. coli knock-out 
strains for cyoE, nuoB, poxB and ldhA were obtained from the Keio collection (Coli 
Genetic Stock Center) (Baba et al., 2006). Gene knockouts and insertions were 
transferred into the desired strains by P1 transduction, and kanamycin markers were 
removed using the plasmid pCP20, as previously described (section 2.2.2). Deletions and 
insertions were confirmed by colony PCR (Table 3.2). Chemicals were obtained from 
Sigma-Aldrich. Phusion polymerase (New England Biolabs) was used for cloning 
purposes, and Taq DNA polymerase (Fermentas) was used for colony PCR. Plasmids 
were isolated using the GeneJET Plasmid Miniprep Kit (Thermo Scientific) and PCR 
products were purified using the QIAQuick Gel Extraction Kit (QIAGEN). For routine 
propagation, strains were grown in LB. Appropriate antibiotics (100 μg/mL ampicillin, 
20 μg/mL chloramphenicol, 12.5 μg/mL tetracycline and/or 25 μg/mL kanamycin) were 
added to cultures for plasmid maintenance. Primers used in this Chapter are listed in 
Table 3.2, while strains and plasmids used in this Chapter are listed in Table 3.1.
78
Table 3.1 Strains and plasmids used in Chapter 3 
Strain Genotype / description Reference
DH5α
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 
relA1 endA1 thi-1 hsdR17 Invitrogen
JW0418-1
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), ΔcyoE785::kan, λ-, rph-1, 
Δ(rhaD-rhaB)568, hsdR514 (Baba et al., 2006)
JW5875-2
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, ΔnuoB769::kan, rph-1, 
Δ(rhaD-rhaB)568, hsdR514 (Baba et al., 2006)
JW0855-1
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, ΔpoxB772::kan, rph-1, 
Δ(rhaD-rhaB)568, hsdR514 (Baba et al., 2006)
JW1375-1
F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, ΔldhA744::kan, rph-1, 
Δ(rhaD-rhaB)568, hsdR514 (Baba et al., 2006)
CC023
MG1655, ΔispB, ubiC::LLACC, aroB::LTAA + pTUbiAeDPSo + pMBIS + 
pMtSa This study
CC024
MG1655, ΔispB,  ΔcyoE, ubiC::LLACC, aroB::LTAA + pTUbiAeDPSo +
pMBIS + pMtSa This study
CC025
MG1655, ΔispB, ΔnuoB, ubiC::LLACC, aroB::LTAA + pTUbiAeDPSo +
pMBIS + pMtSa This study
CC026
MG1655, ΔispB, ΔackA-pta, ubiC::LLACC, aroB::LTAA + pTUbiAeDPSo
+ pMBIS + pMtSa This study
CC027
MG1655, ΔispB, ΔackA-pta, ΔpoxB, ubiC::LLACC, aroB::LTAA +
pTUbiAeDPSo + pMBIS + pMtSa This study
CC028
MG1655, ΔispB, ΔackA-pta, ΔpoxB, Δldha, ubiC::LLACC, aroB::LTAA +
pTUbiAeDPSo + pMBIS + pMtSa This study
CC029
MG1655, ΔispB, ΔackA-pta, ΔpoxB, Δldha, ubiC::LLACC, aroB::LTAA +
pTUbiAeDPSo + pMBIS + pMtSaLTAA This study
Plasmid Description Reference
pKD4









pTUbiAeDPSo pTrc99A derivative containing ubiAe and DPSo; AmpR This study
pALTAA pALac derivative containing tktA, aroFFBR and aroB; CmR This study
pMBIS pTrc99A derivative containing DPSo; AmpR This study
pMtSa pBAD33 derivative containing atoB, HMGS, SaHMGR ; CmR (Ma et al., 2011)
pMtSaLTAA
pBAD33 derivative containing atoB, HMGS, SaHMGR, tktA, aroFFBR and 
aroB; CmR This study
Table 3.2 Oligonucleotides used in Chapter 3 






























3.2.2 Aerobic flask fermentation  
Tested strains were streaked from glycerol stocks on M9  medium (Sambrook et 
al., 1989) supplemented with 1.5% agar and 2% glucose and appropriate antibiotics (100 
μg/mL ampicillin, 20 μg/mL chloroamphenicol, 12.5 μg/mL tetracycline and/or 25 
μg/mL kanamycin). After two days of incubation, several colonies were used to inoculate 
5 mL pre-cultures on M9 medium supplemented with 3% glucose, or with an alternative 
carbon source and 0.1% glucose, and antibiotics. Pre-cultures were grown overnight, then 
spun down and adjusted to OD600=1 in fresh M9 medium with 3% glucose or an 
alternative carbon source. Re-suspended pre-cultures were used to inoculate 50 mL 
medium in 250 mL flasks to OD600=0.1. Flasks were shaken at 200 rpm and 37°C for five 
days, with regular sampling to monitor optical density, quinone production and 
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metabolite secretion. Sodium succinate and sodium pyruvate were used as a source of 
succinate and pyruvate, respectively. 
3.2.3 Deletion of the ackA-ptA locus 
The ackA-pta locus was deleted from the chromosome of E. coli using lambda 
Red recombination (Datsenko and Wanner, 2000). A 1597-bp deletion cassette was 
amplified using primers ackapta-koF and ackapta-koR, and the plasmid pKD4 as a 
template. The PCR reactions were purified, treated with DpnI, and dialyzed using a 0.025 
μm disc (Millipore). Cells of E. coli MG1655 aroB::LTAA, ubiC::LLACC harboring 
pKD46 that were previously grown on LB containing L-arabinose (15 mM), were 
transformed by electroporation using ~700 ng of the purified DNA cassette. Knock-outs 
were identified by colony PCR using primers ackaptaF and ackaptaR. The kanamycin 
marker flanked by FRT sites was removed using the helper plasmid pCP20, as previously 
described (Datsenko and Wanner, 2000). 
3.2.4 Construction of pMtSa-LTAA 
The plasmid pMtSaLTAA, where the lacZp:tktA-aroFFBR-aroB operon is inserted 
downstream of the MevT operon on the pACYC184 backbone, was constructed using 
Gibson assembly method (Gibson et al., 2009). The lacZp:tktA-aroFFBR-aroB operon was 
amplified in two parts, using primer pairs H1_F/H2_R and H2_F/H4_R and pALTAA as 
template. The pMtSa plasmid was amplified in three parts using primer pairs 
H4_F/H5_R, H6_F/HGMR-R and H8_F/H1_R. PCR products were treated with DpnI
and purified. Six hundred fmol of each part were pooled and evaporated in a speed 
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vacuum concentrator. DNA was re-suspended in 20 μL Gibson Assemby Mix (100 mM 
Tris-HCl (pH=7.5), 5 mM MgCl2, 20 μM dNTPs, 250 μM DTT, 63 μg PEG-8000, 313 
nM NAD, 0.08 U T5 exonuclease, 0.5 U Phusion DNA polymerase, 80 U Taq DNA 
ligase), then incubated at 50°C for 60 minutes. Ten μL of the completed reaction was 
used for transformation in DH5α. Positive clones were screened by colony PCR using 
primer pairs H3_F/H5_R and H8_F/H2_R.  
3.2.5 Quinone extraction and analysis 
Cells from one-mL aliquots of E. coli cultures were harvested at 16,100 x g for 
analysis of their quinone content. The pelleted cells were washed with 1 mL of 50 mM 
Tris-HCl pH 7.5, and re-suspended in 450 μL Cell Lytic B (Sigma-Aldrich). After 30 
minutes at room temperature, a first extraction was performed with 900 μL of hexane:2-
propanol (5:3). The upper phase was transferred into a new tube and a second extraction 
was done using 500 μL of hexane. The combined extracts were dried under a nitrogen 
stream, and re-suspended in 100 μL acetone. A 10-μL aliquot was injected into a 1200 
Series HPLC system equipped with a ZORBAX Eclipse XDB-C18 (4.6 x 150 mm, 5 μm, 
Agilent technologies). The mobile phase consisted of acetonitrile (A) and ethanol (B), ran 
at 0.5 mL/minute with the following elution profile: 0-5 minutes, 40% B; 5-11 minutes, 
40%-100% B; 11-22 minutes, 100% B. The quinones were detected at 275 nm. CoQ10 
was quantified using a standard curve of an authentic standard. 
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3.2.6 Extracellular metabolite analysis 
For HPLC analysis of extracellular metabolites, one-mL aliquots from E. coli
cultures were centrifuged at 16,100 x g to remove the cells. The supernatant was filtered 
using a 13 mm 0.2 μM nylon filter (Acrodisc, VWR), and 10 μL was injected into a 
Finnigan Surveyor HPLC System (Thermo) equipped with an Aminex HPX-87H column 
(Bio-Rad) heated to 65°C. Acetic acid, pyruvic acid, lactic acid and glucose were 
resolved using 10 mM H2SO4 at a flow rate of 0.6 mL/minute and detected with a 
Finnigan Surveyor UV/Vis Plus Detector (Thermo) at 210 nm, except glucose which was 
detected using a Differential Refractometer (Waters 410). PHB and Unknown 1 were 
resolved using 10 mM H2SO4 and 15% acetonitrile at a flow rate of 0.6 mL/minute and 
detected at 254 nm. All metabolites were quantified using a standard curve of authentic 
standards. 
3.3 Results 
3.3.1 CoQ10 production on different carbon sources 
As a first step to explore the interplay between central metabolism and CoQ10 
production, I tested the impact of different carbon sources on strain CC023, under aerobic 
shake-flask conditions. To simplify carbon fluxes and data interpretation, experiments 
were done in M9 minimal medium. Carbon sources were chosen to reflect different entry 
points in central metabolism, different uptake mechanisms and different oxidation states. 
Glucose is transported inside the cell and concomitantly phosphorylated at the expense of 
PEP, entering glycolysis, and then the TCA cycle. Glycerol enters the cell by facilitated 
diffusion and is then metabolized mainly to glycerol-3-phosphate, then to 
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dihydroxyacetone phosphate, where it enters glycolysis (Voegele et al., 1993). Pyruvate 
is transported into cells by an active transport system, and may then undergo 
decarboxylation to acetyl-CoA, oxidation to acetate or phosphorylation to PEP (Lang et 
al., 1987). The C4-carbon succinate is imported by a proton-coupled transporter, then 
enters the TCA cycle and triggers the onset of gluconeogenesis reactions (Gutowski and 
Rosenberg, 1975) (Figure 3.1).  Figure 3.2 summarizes the growth pattern and CoQ10 
contents obtained on different concentrations of glucose, glycerol, pyruvate and 
succinate. In this experiment, excess glucose (3%) allowed the most robust growth and 
the largest CoQ10 production (Figure 3.2A). However, growth and CoQ10 production of 
CC023 on the selected carbon sources was variable between experiments and replicates 
(see Appendix, section A2). Reduced growth rate and final biomass on substrates other 
than glucose suggest that they can difficultly sustain both growth and the strong pull 
exerted by the engineered aromatic and isoprenoid pathways in strain CC023 (Figure 
3.2C, D). Growth on glycerol did not markedly increase CoQ10 production, indicating 
that neither catabolite repression nor the transport of glucose at the expense of PEP limits 
CoQ10 production in strain CC023 (Figure 3.2B). Based on these results, I concluded 
that alternative patterns of catabolic and anabolic reactions brought about by glycerol, 
pyruvate and succinate did not markedly favor CoQ10 production.  
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Figure 3.2 Growth and production of CoQ10 on difference carbon sources  
Strain CC023 was grown on A) glucose B) glycerol C) pyruvate D) succinate. For each 
substrate, three concentrations were tested: 0.3% (diamonds), 1% (squares) or 3% 
(triangles). Samples were taken after 23, 29, 71 and 160 hours in order to monitor optical 
density (dashed lines, empty shapes) and CoQ10 production (full lines, filled shapes). 
3.3.2 Altering the electron transport chain for CoQ10 production 
CoQ10 is an essential component of the electron transport chain of E. coli. As 
such, inherent control mechanisms allow cells to modulate the biosynthesis of ubiquinone 
depending on their respiratory state (Shestopalov et al., 1997). Such mechanisms are 
complex with multiple layers of control, hindering our capacity to engineer precise 
modulations in their onset. By altering the electron transport chain directly, I 
hypothesized that transcriptional and/or post-translational control mechanisms of 
ubiquinone production could be harnessed, increasing CoQ10 accumulation in CC023. 









































































































































membrane-bound NADH dehydrogenase (4 H+ translocated/ 2 electrons) (Figure 3.1)
(Erhardt et al., 2012). A ∆nuoB strain may undergo respiration using NADH 
dehydrogenase II (ndh) and WrbA, but with lower efficiency (0 H+/2 eletrons) (Bekker et 
al., 2009; Ingledew and Poole, 1984). The gene cyoE encodes a farnesyl transferase 
catalyzing the condensation between a prenyl group and proheme IV, to form heme o, as 
part of the cytochrome bo’ oxidase (Saiki et al., 1992). Three terminal oxydases may be 
expressed during aerobic respiration: cytochrome bd I oxidase (cydAB), cytochrome bd II
oxidase  (appCB) and cytochrom bo’ oxidase (cyoABCDE) (Figure 3.1). Cytochrome bd
has high affinity to O2 and is expressed during microoxic conditions, while cytochrome 
bo’, with lower affinity to O2, is highly expressed in aerobic conditions and is the only 
terminal oxidase acting as a proton pump (Ingledew and Poole, 1984). Deletion of cyoE
results in the replacement of heme o by heme b, and in a structurally intact but inactive 
cytochrome bo’ oxidase (Saiki et al., 1992). I hypothesized that mutations in either 
ΔnuoB or ΔcyoE, although not entirely disruptive of aerobic respiration, would restrict 
the activity of the respiratory chain and trigger endogenous mechanisms for the 
upregulation of ubiquinone biosynthesis.  The ΔcyoE and ΔnuoB mutations were thus 
introduced in CC023, yielding CC024 and CC025, respectively. As shown by Figure 3.3,
neither ΔnuoB nor ΔcyoE had a significant impact on CoQ10 accumulation.  
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Figure 3.3 CoQ10 production in response to mutations in the aerobic respiratory 
chain 
Strains CC023, CC024 and CC025 were grown for five days and sampled for CoQ10 
production. Error bars show the standard deviation of three biological replicates. 
3.3.3 Effect of redox change on CoQ10 production 
Despite the absence of significant improvement in CoQ10 synthesis in strains 
carrying mutations in the respiratory chain (section 3.3.2) or grown on alternative carbon 
sources (section 3.3.1), I continued the investigation into possible interactions between 
CoQ10 production and central metabolism, shifting my focus towards redox homeostasis.  
To assess the effect of NADH availability on CoQ10 production, carbon sources with 
different oxidation states were tested. Gluconate (oxidation state: +1) metabolism 
bypasses the reduction of one mole of NADH per mole of substrate consumed, compared 
to glucose (oxidation state: 0). Conversely, the catabolism of sorbitol (oxidation state: -1) 
leads to the reduction of one mole of NADH more than glucose per mole consumed 
(Figure 3.4A) (Lin et al., 2005). The production of CoQ10 by CC023 increased over two-
fold when grown on sorbitol, compared to glucose and gluconate (Figure 3.4B). These 
results suggested that a high NADH/NAD+ ratio favors CoQ10 production, and prompted 
me to revisit the effect of the ∆cyoE and ∆nuoB mutations in the context of sorbitol 




















and ∆nuoB mutations, respectively, produced equivalent amounts of CoQ10 as CC023 on 
sorbitol. No direct connection could thus be established between the activity of NADH-
dehydrogenase I, cytochrome bo’ oxidase and the effect of sorbitol on CoQ10 production. 
Figure 3.4 Effect of carbon substrates of different oxidation states on CoQ10 
production  
A) Catabolism of gluconate, glucose and sorbitol. Gluconate-6P, gluconate 6-phosphate; 
GAP, glyceraldehyde-3-phosphate; DHAP, dihydroxyacetone phosphate; glucose-6P, 
glucose 6-phosphate; fructose-6P, fructose 6-phosphate; fructose 1,6-biP, fructose-1,6-
bisphosphate; glycerate-1,3-biP, glycerate 1,3-bisphosphate; PEP, phosphoenolpyruvate; 
sorbitol-6P, sorbitol 6-phosphate; ATP, adenosine triphosphate; ADP, adenosine 




























































































following five days of aerobic flask fermentation on the indicated carbon substrate. C)
CoQ10 production in strains CC023, CC024 and CC025 following five days of aerobic 
fermentation on sorbitol. Error bars represent the standard deviation of two (A) or three (B) 
biological replicates. 
3.3.4 CoQ10 production and metabolite excretion profile on sorbitol 
To investigate further the link between sorbitol metabolism and CoQ10 
production, the accumulation of CoQ10 and of intermediate metabolites were followed 
over a time-course of five days. CC023 grew to slightly higher density on sorbitol (Figure 
3.5B).  Sorbitol was consumed at a lower rate, but over a longer period than glucose 
(Figure 3.5B). The production of CoQ10 in CC023 grown on sorbitol was sustained over 
124 hours, whereas CC023 grown on glucose reached maximum CoQ10 content by 48 
hours (Figure 3.5A). Strain CC023 produced over three-times more CoQ10 on sorbitol 
than on glucose, reaching 3.5 mg/g DCW of CoQ10. The accumulation pattern of PHB 
on glucose was characterized by the early excretion of 0.009 mM of PHB, of which 26% 
was consumed by 24 hours. On sorbitol, half of the secreted PHB was consumed between 
24 and 51 hours, correlating with the two-fold increase in CoQ10 production observed 
during that period (Figure 3.5C). A drastic difference in acetate excretion was observed 
between the two conditions. Growth on glucose led to the accumulation of 80 mM acetic
acid in the growth medium, while less than 10 mM of acetate was secreted during sorbitol 
fermentation, all of which consumed by 51 hours (Figure 3.5E).  Minimum lactate was 
detected, under both conditions (Figure 3.5F). Up to 0.7 mM of pyruvate accumulated 
after 24 hours of growth on sorbitol, while only 0.4 mM was secreted by cells grown on 
glucose, after 100 hours of fermentation (Figure 3.5F). On both glucose and sorbitol, I 
observed the accumulation of an unidentified metabolite with strong absorption at 210 
nm and 254 nm, named Unknown 1. Cells grown on sorbitol produced 2.4-fold more of 
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this compound compare to those grown on glucose, up to 51 hours. After this point, 
Unknown 1 was consumed almost entirely by strain CC023 grown on sorbitol, while it 
remained stable in the glucose medium (Figure 3.5D). Analytical experiments using LC-
MS were performed in order to identify Unknown 1, but were unsuccessful (Appendix, 
section A6).
Figure 3.5 Time-course of CoQ10 production and metabolite secretion during aerobic 
flask fermentation on glucose and sorbitol (2012) 
Strain CC023 was grown for five days on glucose (triangles) or sorbitol (squares), in 
August 2012. Samples were taken after 0, 5, 24, 51, 80, 100, and 124 hours to measure A)






































































































































































and sugar consumption (empty shapes) C) extracellular PHB D) extracellular Unknown 1
E) extracellular acetate F) extracellular lactate (filled shapes) and pyruvate (empty shapes). 
Error bars show the standard deviation from three biological replicates. 
3.3.5 Elimination of acetate production pathways 
The most striking difference in metabolic profile between CC023 grown on 
sorbitol and glucose was the flux to acetate (Figure 3.5E). This prompted me to 
investigate the link between acetate production and CoQ10 accumulation. Two major 
biosynthetic pathways to acetate exist in E. coli: 1) the conversion of acetyl-CoA to 
acetyl phosphate by a phosphotransacetylase (encoded by pta) followed by the 
conversion of acetyl phosphate to acetate by an acetate kinase (ackA), yielding one 
adenosine triphosphate (ATP) and 2) the oxidation of pyruvate to acetate by pyruvate 
oxidase (poxB), with ubiquinone as an electron acceptor (Figure 3.1). The Pta-AckA 
pathway to acetate formation is mainly active during exponential phase, while poxB is 
up-regulated during late exponential and stationary phases (Dittrich et al., 2005). Two 
hypotheses drove my experimental design. First, as one mole of ATP is produced with 
each mole of acetate formed via the Pta-AckA route, the elimination of this pathway may 
lead cells to increase respiration to maintain ATP levels, indirectly triggering the up-
regulation of the ubiquinone pathway. Alternatively, reducing acetate production, by 
eliminating both ackA-pta and poxB, may push more carbon towards CoQ10 
intermediates. As fifteen moles of acetyl-CoA are required per mole of CoQ10 produced, 
I reasoned that a decrease in acetate production should translate in increased acetyl-CoA 
availability for the mevalonate pathway. To test these hypotheses, I introduced ∆ackA-pta
alone or ∆ackA-pta ∆poxB in strain CC023, yielding CC026 and CC027, respectively 
(Table 3.1). These mutations had a slightly positive effect on biomass production in 
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CC027, compared to CC023 (Figure 3.6B). As expected, excreted acetate went down 
from 45 mM for CC023 to 15 and 7 mM for CC026 and CC027, respectively (Figure 
3.6E). The downregulation of acetate biosynthetic pathways in CC026 and CC027 was 
compensated by an increase in lactate production, compared to CC023 (Figure 3.6F). 
Both CC026 and CC027 accumulated more pyruvate than CC023 (Figure 3.6G). The 
∆ackA-pta mutation alone had no effect on CoQ10 production. However, CC023, 
carrying the mutations ∆ackA-pta ∆poxB, displayed a 1.5-fold increase in CoQ10 content. 
There was also a two-fold decrease in 10P-Ph accumulation in CC027 compared with 
CC023 (Figure 3.6A). Enhanced CoQ10 production in strain CC027 was correlated with 
a 3.2-fold increase in excretion of Unknown 1, compared to CC023 (Figure 3.6D). 
Overall, my results show that elimination of the ATP-yielding route (ackA-pta) to acetate 
production is not sufficient to improve CoQ10 content. Instead, both major acetate 
biosynthetic pathways must be deleted for CoQ10 production to go up. 
Deleting the acetate biosynthetic pathways did not entirely mimic sorbitol 
metabolism, and the CoQ10 yields are not as high in CC027 as previously observed in 
CC023 on sorbitol (Figure 3.5A). No detectable PHB remained in the media by 24 hours, 
suggesting that it may have become limiting during fermentation (Figure 3.6C). Unknown 
1, excreted and then consumed during growth on sorbitol (Figure 3.5D), remained at high 
concentration in the medium throughout fermentation of strain CC027 (Figure 3.6D). In 
addition, accumulation of lactate had not been observed in CC023 grown on sorbitol, and 
suggests that part of the carbon diverted from acetate excretion, instead of being 
channeled towards CoQ10 biosynthesis, is taking an alternative fermentation route
(Figure 3.5F; Figure 3.6F).   
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Figure 3.6 Time-course of CoQ10 production, growth, and metabolite accumulation 
following the deletion of acetate producing pathways 
Strains CC023 (circles), CC026 (squares) and CC027 (triangles) were grown for five days 
on glucose. Samples were taken after 0, 8, 28, 68 and 120 hours to measure A) CoQ10 













































































































































PHB D) extracellular Unknown 1 E) extracellular acetate F) extracellular lactate G)
extracellular pyruvate. Error bars show the standard variation of three biological replicates. 
As these experiments were carried out, a year after the experiments reported in 
sections 3.3.1 to 3.3.4, I started to observe increased variability between replicates, and 
sometimes significantly reduced accumulation of CoQ10 in my engineered strains. In 
particular, at this time, attempts to replicate experiments on sorbitol reported in sections 
3.3.3 and 3.3.4 were unsuccessful, despite the reproducibility of the phenotype in initial 
experiments (see Appendix, section A3). The profile of excreted metabolites by the 
engineered strains also changed between 2012 and 2013. Notably, lactate and pyruvate 
excretion markedly increased in 2013 (Figure 3.4, Figure 3.5, Figure A 7).
3.3.6 Elimination of lactate and acetate production pathways 
In an effort to direct carbon away from mixed-fermentation products and towards 
CoQ10 biosynthesis, the gene coding for lactate dehydrogenase, ldhA, was deleted and 
the mutation combined with the acetate biosynthesis mutations, yielding CC028 (Figure 
3.1, Table 3.1). The ldhA knockout completely eliminated lactate production in strain 
CC028 (Figure 3.7G). However, this did not translate in increased CoQ10 production, 
compared to the inactivation of the acetate pathways alone, with both strain accumulating 
2.5-3 mg/g DCW of CoQ10 (Figure 3.7A). In this experiment, I found one replicate of 
CC028 with significantly lower CoQ10 content, CC028c. As I had started to observe 
reduced reproducibility in my experiments using CoQ10 producing strains, the analysis 
of a culture with reduced CoQ10 production provided an opportunity to gain insight 
about this instability. Metabolite distribution was compared between the two tested 
strains and the CC028c outlier. The deletion of ldhA in CC028 resulted in higher 
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accumulation of pyruvate (Figure 3.7H).  Pyruvate excretion reached 27 mM in CC028, 
and went up to 37 mM in CC028c, a 1.9-fold increase compared to CC027 (Figure 3.7F). 
The accumulation of pyruvate was inversely correlated with the glucose uptake, which 
reached 135 mM in CC027 but only 88 mM and 65 mM in CC028 and CC028c, 
respectively (Figure 3.7C). PHB production went up to 0.005-0.007 mM PHB, consumed 
within 53 hours by CC027 and CC028, but not by CC028c which only consumed one 
third the secreted PHB over the course of fermentation (Figure 3.7D). The levels of 
Unknown 1 were also three times lower in CC028c compared to CC027 and CC028, 
correlating with lower CoQ10 production in CC028c (Figure 3.7B, E). Overall, my
results show that the elimination of the lactate biosynthetic route, in a ∆ackA-pta ∆poxB
background, introduces a bottleneck at the pyruvate node, restricting carbon flux towards 
CoQ10 production. This effect is exacerbated in CC028c, where even higher pyruvate 
secretion is associated with lower glucose uptake, reduced PHB consumption and inferior 
CoQ10 content. 
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Figure 3.7 Time-course of CoQ10 production, growth, glucose uptake and metabolite 
secretion following the deletion of acetate and lactate production pathways 
Strains CC027 (full circles) and CC028 (full triangles, empty triangles for CC028c) were 
grown for five days on glucose. Samples were taken after 0, 6, 12, 24, 53, 74, 96 and 120 






































































































































































density C) glucose uptake D) extracellular PHB E) extracellular Unknown 1 F)
extracellular acetate G) extracellular lactate H) extracellular pyruvate. Error bars show the 
standard deviation of two or three biological replicates. 
3.3.7 Increasing the production of PHB 
In order to accommodate the expression of the plasmid pMtSa, I had chosen to 
transfer the recombinant top aromatic operon on E. coli’s chromosome (section 2.3.6). 
This had translated in a significant decrease in PHB production (Figure 3.5E), but the 
aromatic precursor remained in excess. Metabolite analyses presented in sections 3.3.5
and 3.3.6 show that while the amount of PHB excreted during exponential phase 
remained the same, the aromatic molecule was then entirely consumed from the 
fermentation medium by 24 hours, suggesting that PHB may become rate-limiting during 
the CoQ10 production phase, which typically extends up to 120 hours. In order to 
increase flux through the aromatic pathway, I inserted an additional copy of the upper 
aromatic operon on the plasmid pMtSa, yielding pMtSaLTAA. This plasmid was 
introduced in the CoQ10 production strain CC028, yielding CC029 (Table 3.1). Again, 
there was variability between replicates. CC028 produced less CoQ10 than previously 
reported, with only 1.5 mg/g DCW of CoQ10, similarly as CC028c in the experiment 
reported in section 3.3.6 (Figure 3.7A, Figure 3.8B). Despite a 2.9-fold increase in initial 
PHB production compared to CC028, strain CC029 had comparable CoQ10 content as 
CC028, except for one replicate, CC029b, which accumulated up to 2.7 mg/g DCW of 
CoQ10 (Figure 3.8B, C). Secretion of Unknown 1 in CC028 and CC029 was similar to 
what I had observed before in strains accumulating lower levels of CoQ10, except for 
CC029b, which accumulated 2.4 times more of Unknown 1 (Figure 3.8D). Similarly to 
what was reported for CC028 in section 3.3.6, all strains excreted more than 26 mM 
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pyruvate (Figure 3.7H, Figure 3.8E).  In agreement with the genotype of the tested 
strains, no significant accumulation of acetate and lactate was observed in the growth 
medium (not shown).  
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Figure 3.8 Time-course of CoQ10 production, growth and metabolite secretion 
following the expression of a plamid-localized copy of the upper aromatic operon 
Strains CC028 (filled circles) and CC029 (filled triangles, empty triangles for CC029b) 
were grown for five days on M9-glucose medium. Samples were taken after 0, 24, 72, and 
120 hours to measure A) CoQ10 (full lines) and 10P-Ph (dashed lines) production B)
optical density C) extracellular PHB D) extracellular Unknown 1 E) extracellular pyruvate. 
Error bars show the standard deviation of two or three biological replicates. 
3.4  Discussion 
In this chapter, I investigated how central metabolism may influence CoQ10 







































































































pathways, or indirectly by triggering upregulatory mechanisms for ubiquinone 
accumulation.  
3.4.1 Modulations in CoQ10 production using selected carbon sources 
The source of carbon available to E. coli is expected to result in variations of 
intracellular metabolic fluxes (Holms, 1996). In addition, transcriptional activity may be 
differentially modulated by alternative substrates, due to catabolite repression. My 
hypothesis was that carbon sources such as glycerol, pyruvate or succinate may enhance 
the production of CoQ10 in CC023, thereby shedding light on unknown control 
mechanisms limiting the production of CoQ10 in my engineered strain. None of the 
carbon source tested led to increased CoQ10 production in strain CC023. However, 
differences were observed in the growth rate and final biomass obtained on these 
substrates compared to glucose (Figure 3.2). As the engineered pathways consume 
increased amounts primary metabolites (PEP, E4P, acetyl-CoA), less energy-efficient 
carbon sources than glucose requiring the onset of gluconeogenesis reactions may 
difficultly sustain growth. Variations in CoQ10 production and growth between 
experiments may also reflect high selection pressure for mutations resulting in decreased 
flux to CoQ10, to either maintain pools of primary metabolites (PEP, E4P, acetyl-CoA) 
or to bypass the accumulation of toxic compounds (CoQ10 or intermediates) (see 
Appendix, section A2). Overall, these experiments provided the first clues that the dual 
pull on PEP and acetyl-CoA exerted by the engineered pathways, or the accumulation of 
CoQ10, create a burden on the primary metabolism of my engineered strains.  
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3.4.2 Altering the electron transport chain for CoQ10 production 
The introduction of mutations in nuoB and cyoE intended to mimic restrictions in 
electron flux through the respiratory chain susceptible to trigger an upregulation of 
CoQ10 production. This hypothesis was based on reports that microaerobic conditions or 
treatment with respiration inhibitors stimulate CoQ10 production in microbes (Choi et al., 
2005; Ha et al., 2007b; Seo and Kim, 2010). However, I did not observe differences in 
CoQ10 production in strains CC024 and CC025, bearing the ∆cyoE and ∆nuoB 
mutations, respectively, compared to CC023. As illustrated in Figure 3.1, the respiratory 
chain of E. coli is complex and redundant, with multiple NADH dehydrogenases and 
terminal oxidases, whose expressions vary depending on oxygen availability. A more 
systematic study including multiple combinations of mutations may be more appropriate 
to restrict electron flux through the respiratory chain in E. coli. An additional caveat in 
my hypothesis is that the positive effects of azide and microaerobic conditions on CoQ10 
production were only observed in R. radiobacter and R. sphaeroides. These naturally 
high producers of CoQ10 use cytochrome c, in addition to ubiquinone, but unlike E. coli
lack naphthoquinones. Such inherent differences may influence the cell’s response to 
restricted flux in the electron transport chain. In addition, E. coli uses the redox state of 
its ubiquinone pool as a signal for the onset of aerobic/anaerobic metabolism (Georgellis 
et al., 2001). Promoter studies with different genes of the ubiquinone pathway have 
shown that the biosynthesis of ubiquinone is under the control of central transcriptional 
regulators including ArcA/B and FNR (Kwon et al., 2005; Soballe and Poole, 1997; 
Zhang and Javor, 2003). The accumulation of 10P-Ph, under conditions where the 
production of both PHB and isoprenoid precursors are deregulated, also points towards 
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an intrinsic regulation system that prevents the accumulation of high amounts of CoQ10 
in engineered E. coli. The maximum CoQ10 content obtained in strain CC023, 3.5 mg/g 
(Figure 3.4C, Figure 3.5A), is comparable to what was previously reported in E. coli 
using different engineering strategies (Huang et al., 2011; Zahiri et al., 2006b). There 
may therefore be significant physiological restraints to maintain the ubiquinone pool 
within a given size range. 
3.4.3 Sorbitol and the production of increased levels of CoQ10 
The effect of sorbitol on CoQ10 production reported in sections 3.3.3 and 3.3.4
demonstrates that central metabolism can influence the synthesis of this antioxidant. 
Sorbitol has a lower oxidation state than glucose, and its catabolism produces more 
reducing equivalent, in the form of NADH. Under anaerobic conditions, to achieve redox 
balance, E. coli grown on sorbitol directs carbon flow towards the synthesis of more 
reduced products, typically ethanol and lactate, at the expense of acetate (Lin et al., 2005; 
San et al., 2002). Little is known about sorbitol metabolism under aerobic conditions. I 
observed a marked decrease in acetate production when CC023 was grown on sorbitol, 
but no ethanol was detected and I was not able to identify a more reduced product 
accumulating in the growth medium (Figure 3.5). It is possible that cells were able to 
achieve redox balance by increasing the activity of the aerobic respiratory chain. 
However, the ∆nuoB and ∆cyoE mutations did not alter fluxes to acetate (not shown). 
Therefore, it is unclear whether this mechanism is used to achieve redox homeostasis. 
Flux analysis of E. coli grown on fructose reveals a metabolic partition where no carbon 
goes to acetate, but acetyl-CoA is instead redirected to the TCA cycle (Holms, 1996). 
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Similarly, E. coli B strains secrete less acetate because of an upregulation of the 
glyoxylate bypass, resulting in more acetyl-CoA being pulled by the TCA cycle (van de 
Walle and Shiloach, 1998). Although I was not able to resolve TCA cycle intermediates 
with confidence in my analysis, I found that the secretion of molecules that may 
correspond to citrate, isocitrate α-ketoglutarate or oxaloacetate, displayed a different 
pattern on sorbitol compared to glucose (see Appendix, Figure A 8). It is possible that on 
sorbitol, CC023 maintained anaplerotic fluxes and TCA cycle activity after growth arrest, 
resulting in sustained glucose uptake, glycolysis and carbon flux towards CoQ10 
biosynthesis throughout fermentation, and well beyond the stationary phase. It is also 
possible that increased CoQ10 production is solely linked to the higher availability of 
acetyl-CoA resulting from reduced flux to acetate. Enhanced CoQ10 production in a 
∆ackA-pta ∆poxB mutant, CC027, supports this hypothesis (Figure 3.6). Alternatively, 
transcriptional upregulation of the ubiquinone pathway, in response to the altered redox 
status or to pH, may also play a role in enhancing CoQ10 biosynthesis. More precise 
analyses of intracellular metabolites, enzymatic activity, and transcriptional activity 
would be required in order to fully understand the link between sorbitol and CoQ10 
production in CC023.  My incapacity to observe the same phenotype on sorbitol in 2013 
precluded such an investigation. On both glucose and sorbitol, metabolic activity in 
CC023 appeared changed between 2012 and 2013. On glucose, in 2013, less PHB was 
excreted into the medium, and more pyruvate and lactate were secreted, at the expense of 
acetate (Figure A 7). On sorbitol, more PHB was secreted in the medium early during 
fermentation compared to 2012, suggesting that the aromatic pathway was active, but that 
the PHB produced was not incorporated into CoQ10 (Figure A 7). My analysis is clearly 
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hindered by the lack of information about the production of isoprenoid precursors in 
CC023. A comparison of the accumulation pattern of FPP/DPP might not only have 
provided clues on the mechanism behind the positive effect of sorbitol on CoQ10 
production, but also on the absence of this effect observed in 2013.  
3.4.4 Elimination of acetate and lactate production pathways to enhance CoQ10 
production 
I was able to partially reproduce the phenotype first observed on sorbitol by 
deleting acetate production pathways, suggesting at least a coincidental link between 
CoQ10 and acetate secretion. However, there are differences in metabolic flux 
distribution between CC027 (Figure 3.6) and CC023 on sorbitol (Figure 3.5). In 
particular, the accumulation of pyruvate in CC027 was not observed on sorbitol. 
Secretion of pyruvate has been reported in strains carrying the ∆pta or ∆ackA-pta ∆poxB
mutations, and has been proposed to result from the inhibition of pyruvate dehydrogenase 
(Dittrich et al., 2005; Kakuda et al., 1994).  The accumulation of pyruvate was further 
enhanced by preventing lactate production (∆ldhA), especially in CC028c, which 
correlated with decreased glucose uptake, and lower CoQ10 content (Figure 3.7A, C). As 
strain CC028 cannot recycle NADH to NAD+ using lactate dehydrogenase, a high 
NADH/NAD+ ratio may result in the inhibition of pyruvate dehydrogenase by NADH 
(Figure 3.1) (Schmincke-Ott and Bisswanger, 1981), leading to the observed 
accumulation of pyruvate. Supporting this hypothesis, I was able to decrease pyruvate 
secretion in CC027 using fed-batch fermentation, where oxidative respiration and NADH 
recycling to NAD+ is favored by limiting the glucose supply (see Appendix, Figure A 
10).  The accumulation of pyruvate in aerobic flask fermentation reduces the 
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PEP/pyruvate ratio, which may lead to lower glucose uptake (Liao et al. 1996, Patnaik et 
al. 1992). The activity of pyruvate dehydrogenase also controls flux to acetyl-CoA, and to 
the mevalonate pathway. There might therefore be high selective pressure to 
downregulate flux to this foreign metabolic branch. I succeeded in increasing the 
production of CoQ10 by abrogating acetate biosynthesis, but it remains unclear whether 
this is due to a larger pool of acetyl-CoA being pulled by the mevalonate pathway, or by 
indirect effects on the activity of the ubiquinone pathway. As previously mentioned, an 
analysis of isoprenoid accumulations patterns should provide clues to answer that 
question.  
3.4.5 Availability of PHB for CoQ10 production 
The five-days flask fermentations were often characterized by the secretion of 
PHB during the first 24 hours, followed by its complete consumption between 48 and 120 
hours (Figure 3.6C, Figure 3.7D, Figure A 7C). This suggests that the aromatic precursor 
may have become limiting to CoQ10 production in these experiments. Extracellular PHB 
was notably lower than what was previously reported on M9 medium supplemented with 
yeast extract, and reported in Chapter 2. The use of minimal medium for CoQ10 
production thus appears to restrain flux through the aromatic pathway, perhaps due to 
increased demand for aromatic amino acids. In previous experiments, extracellular PHB 
concentration also remained more or less stable between 24 and 120 hours of 
fermentation, despite a concomitant increase in CoQ10 content (Figure 3.5, Figure 2.9). It 
is possible that in later experiments, PHB production was sustained throughout 
fermentation and channeled directly to the ubiquinone pathway, bypassing the excretion 
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of this organic acid. The complete consumption of PHB, observed only in experiments 
performed in 2013, may reflect mutations resulting in lower PHB production during the 
stationary phase. As mentioned before, there might be high selective pressure to decrease 
flux of PEP through the engineered aromatic pathway. In order to enhance the activity of 
the shikimate pathway, I added a copy of the top aromatic operon into pMtSa, and 
expressed the resulting plasmid in strain CC029. The fermentation of strains CC028 and 
CC029, except CC029b, was characterized by delays in the accumulation pattern of 
Unknown 1 and CoQ10 compared to previous experiments, which again may be the result 
of unknown mutations (Figure 3.8). The increased PHB production in strain CC029, even 
in CC029b, did not concur with enhanced CoQ10 contents, compared to those previously 
observed (Figure 3.8A). This suggests that the availability of PHB is not limiting CoQ10 
production in my engineered strains. 
3.4.6 Reproducibility and strain stability 
Early in this investigation, I observed that my production strains did not display 
reproducible patterns of growth, metabolite accumulation and CoQ10 production. High 
fluxes towards the aromatic pathway and the foreign mevalonate pathway are certainly 
creating a burden on E. coli’s metabolism. Both PEP and acetyl-CoA, the primary 
substrates of the aromatic and mevalonate pathways, respectively, play pivotal roles in 
central metabolism. PEP is required for the uptake of several carbon substrates, and flux 
partitioning of PEP between pyruvate and oxaloacetate defines the balance between 
biomass production, TCA cycle activity and acetate secretion (Figure 3.1) (Liao et al., 
1994). Acetyl-CoA plays an equally crucial role, at the branchpoint between glycolysis, 
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respiration (via the TCA cycle) and fermentation (via acetate production). The faith of 
these two metabolites is also interdependent: flux of acetyl-CoA to the TCA cycle 
requires the concomitant conversion of PEP to oxaloacetate, and accordingly, acetyl-CoA 
activates PEP carboxylase (Chang et al., 1999; Liao et al., 1994). The pull on these two 
metabolites exerted by the synthetic mevalonate and aromatic pathways in strain CC023 
and its derivatives may lead to stochastic metabolic responses. There might also be high 
selective pressure to restrict fluxes to these deregulated pathways. In order to simplify my 
interpretation of metabolite accumulation, I had chosen to carry all experiments in 
minimal media. By doing so, cells had to use the chosen substrate for all biosynthetic 
reactions as well as for energy production, which may have exacerbated the selective 
pressure to divert carbon away from the engineered pathways. In Chapter 2, I had 
demonstrated that expression of the synthetic operons did not require the addition of 
IPTG, even when grown on glucose (section 2.3.8). It is possible that the burden exerted 
by fluxes towards mevalonate and PHB would have been curtailed by more stringent 
transcriptional control of expression. By inducing their expression late in exponential 
phase, or in stationary phase, the selective pressure to divert carbon flux away from these 
secondary pathways could have been minimized. There might also be plasmid 
instabilities in the engineered strains expressing the three recombinant plasmids, 
pTUbiAeDPSo, pMBIS and pMtSa. Decreased plasmid retention, especially in 
fermentation lasting several days, has been reported when plasmids derived from the 
same vector backbones as those used in this study were co-expressed (Anthony et al., 
2009).  Individual plasmid stability should therefore be assessed in the CoQ10 production 
strains, in order to ensure their compatibility and sustained expression.   
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 Finally, the secretion pattern of Unknown 1 shows that this unidentified 
metabolite is produced concurrently to CoQ10 (Figure 3.6D, Figure 3.7E, Figure 3.8D). 
A notable exception to this was observed on sorbitol, were Unknown 1 accumulated for 
up to 51 hours, and was thereafter consumed from the growth media (Figure 3.5D). This 
led me to hypothesize that Unknown 1 was a ubiquinone intermediate, but my inability to 
extract this compound using hexane does not support such a model (Appendix, section 
A6). Alternatively, Unknown 1 may share precursors with CoQ10, and accumulate by 
pulling intermediates formed via the engineered pathways. The absorption of Unknown 1
at 254 nm suggests that it could be an aromatic molecule, but I was unable to identify the 
compound by mass spectrometry (see Appendix Figure A 11). Future identification of 
Unknown 1 may clarify the link between sorbitol metabolism, acetate biosynthesis and 
CoQ10 production. It may also shed light on an imbalance within the synthetic pathways,
allowing potential improvements of the engineering strategy. 
The premise of this Chapter was that the “base strain”, CC023, could be used to 
develop novel strategies to increase CoQ10 production, by harnessing endogenous 
control mechanisms of carbon fluxes and ubiquinone biosynthesis. However, inherent 
engineering problems in this production strain, leading to instabilities and precursor 
imbalance, have added too many layers of complexity to the results to obtain a clear 
picture of the interplay between E. coli’s central metabolism and CoQ10 production. 
Nevertheless, these experiments have opened several avenues of investigation regarding a 
link between sorbitol catabolism, flux to acetate, and CoQ10 biosynthesis, which should 
be pursued following the optimization of the production strains.  
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Chapter 4. Conclusion and future directions 
The central hypothesis of this thesis was that the identification and upregulation 
of rate-limiting steps in CoQ10 biosynthesis had the potential to result in unprecedented 
accumulation of this molecule in E. coli. Moreover, by investigating metabolic or 
physiological factors influencing the synthesis of CoQ10 in E. coli, I hoped to gain 
insight for the design of novel engineering strategies to maximize carbon flux towards 
CoQ10 biosynthesis. Several original findings were obtained throughout this project, 
opening opportunities for future research to optimize E. coli as a production platform for 
CoQ10. 
I was able to significantly enhance the production of CoQ10 by increasing the 
supply of aromatic and isoprenoid precursors in E. coli, and by overexpressing UbiA, the 
enzyme responsible for the prenylation PHB. However, specific CoQ10 contents in the 
engineered strains remained relatively low considering that PHB was produced in molar 
excess and that the efficiency of the mevalonate pathway (expressed via pMtSa and 
pMBIS) to produce isoprenoids is well documented (Ma et al., 2011). This strongly 
suggests that a portion of the carbon flux directed towards CoQ10 biosynthesis was in 
fact diverted to by-products. The accumulation of Unknown 1, reported in Chapter 3, 
supports this hypothesis. In order to better characterize flux through the engineered 
pathways, it will be primordial to conduct experiments where both aromatic and 
isoprenoid intermediates are quantified. In particular, the complete turnover of FPP/IPP 
into DPP by the heterologous DPSo needs to be ensured. To this end, analytical methods 
have to be developed for the quantification of DPP in vivo. In addition, visualizing 
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detailed carbon partitioning using metabolic flux analysis could reveal the existence of 
competing reactions or of additional bottlenecks in the engineered pathways. Further 
optimization of gene expression or enzyme activity may henceforth be necessary. 
The deregulated production of aromatic and isoprenoid precursors led to the 
accumulation of 10P-Ph, shedding light on a previously unknown bottleneck in the 
ubiquinone pathway.  As discussed in Chapter 2, enzymes of the ubiquinone pathway 
form a putative complex and inadequate activity of several members of this complex may 
lead to an accumulation of 10P-Ph. My results show that increasing PHB 
prenyltransferase (UbiA) activity restrains the accumulation of 10P-Ph. However, 
increasing the activity of the putative monooxygenase UbiI has no effect on 10P-Ph 
production. To abrogate 10P-Ph accumulation altogether, an extensive investigation of 
interactions between enzymes of the ubiquinone pathway will be required. In addition, 
the overexpression of different combinations of Ubi genes in an engineered E. coli strain 
where the production of aromatic and isoprenoid precursors is deregulated may lead to 
the identification of a group of enzymes required to channel 10P-Ph towards CoQ10. 
By investigating the interplay between central metabolism and CoQ10 
biosynthesis in my engineered strains, I found a link between sorbitol catabolism and the 
production of CoQ10. My results suggest that this link is articulated, directly or 
indirectly, around the marked reduction in acetate excretion observed during growth on 
sorbitol. Supporting this hypothesis, higher CoQ10 contents were also observed 
following the deletion of the two main acetate production pathways. In order to 
understand the biology behind these observations, it will be necessary to test the impact 
sorbitol catabolism, as well as of a ∆ackA-pta ∆poxB background, on fluxes towards PHB 
110
or towards mevalonate, in engineered strains expressing these synthetic pathways 
independently. Comparative analyses of transcriptional and metabolic activity in these 
conditions may also shed light on indirect effects of reduced acetate production or altered 
redox status on the expression of genes of the ubiquinone pathway.     
Importantly, these future experiments entail the development of stable engineered 
strains. As documented in Chapter 3, the engineered strains expressing both the 
deregulated aromatic pathway and the complete mevalonate pathway appeared to be 
prone to instabilities and mutations, perhaps because of the dual pull on PEP and acetyl-
CoA. To my knowledge, it is the first instance where two major intermediates of central 
carbon metabolism are simultaneously diverted towards foreign or deregulated pathways. 
The pressure exerted by these abnormal fluxes may lead to the selection of mutations in 
the engineered strains. Metabolic flux analyses would certainly provide insight regarding 
the source of these instabilities and the nature of the selected mutations. Once 
understood, deleterious effects could be circumvented by modulating the intensity and the 
timing of expression the engineered genes. 
Despite the development of rational engineering strategies, the strains developed 
for this thesis were able to accumulate up to 3.5 mg/g CoQ10, which falls in the same 
range as the specific contents reported in other studies (Huang et al., 2011; Zahiri et al., 
2006b). These yields fall below those obtained with R. radiobacter and other natural 
producers of the molecule. It follows that there may be unknown intrinsic factors specific 
to E. coli that prevent the accumulation of high amounts of ubiquinone. Such factors may 
include the ability to spatially accommodate excess ubiquinone in the inner membrane, 
unique regulatory mechanisms to maintain ubiquinone concentrations within a precise 
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range, and native properties of the respiratory chain. The strains of R. radiobacter and R. 
sphaeroides that have been isolated for their high CoQ10 content may provide the key to 
unraveling the underlying mechanisms that favor the production of CoQ10 in microbes. 
Comparative genomic and metabolomic investigations of the ubiquinone pathway and of 
the respiratory chain in these species may elucidate the inherent abilities of these 
organisms to accumulate CoQ10 in their membrane. Lessons learned from these high 
producers may then be applied to inverse engineering industrially-suitable hosts such as 
E. coli. Overall, a better understanding of the limiting factors in the accumulation of 
ubiquinone in E. coli will be essential for this organism to become a suitable platform for 
the industrial production of CoQ10. 
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Appendix 
This appendix contains a selection of experimental data that was judged  
incomplete, non-reproducible, non-conclusive or hampered by technical difficulties. It is 
included here to support certain arguments articulated in Chapters 2 and 3, as well as in 
an effort to leave a clear and complete record of the work accomplished as part of this 
thesis. 
A1. Protein purification of DPSS.bae
I had originally intended to characterize the enzymatic activity of DPSS.bae in 
vitro, and have, to this end, purified DPSS.bae proteins from E. coli cultures. This part of 
the project was not pursued because of the relatively low impact of this type of study, and 
because the complementation of ∆ispB by DPSo (section 2.3.1) provided proof of the 
functionality of the isolated gene.  
The dpsS.bae gene retrieved by inverse PCR from the genomic DNA of S. 
baekryungensis had two putative start codons, and no recognizable ribosome-binding site, 
which originally prompted me to clone two versions of dpsS.bae: dps-L and dps-S. These 
two open-reading frames were cloned into the vector pET19b (Novagen) using  5’ NdeI
and 3’ BamHI restriction sites, yielding pET-DPS-S and pET-DPS-L. I then 
overexpressed and purified both proteins. Colonies of E. coli BL21(DE3) expressing 
pET-DPS-L, pET-DPS-S or pET19b (empty vector control) were inoculated into 4 mL 
LB broth and incubated with shaking for four hours at 37ºC, to an OD600 of 1.8. One mL
from these starting cultures was then transferred to 100 mL LB and incubated at 30ºC for 
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an additional four hours, to an OD600 of 0.9. The temperature of the cultures was rapidly 
brought down to 20ºC on ice, at which point cultures were induced with 0.4 mM IPTG. 
The cultures were then incubated overnight at 20ºC. The following day, cells were 
pelleted by centrifugation and suspended in 10 mL 50 mM Tris pH=7.5 and 1 mM 
phenylmethylsulfonyl fluoride and sonicated using a Sonic Dismembrator (Fisher 
Scientific) at an amplitude of 3, for 1 minute and 40 seconds (pulsar ON for 5 seconds, 
pulsar OFF for 15 seconds). The soluble and insoluble fractions were isolated by 
centrifugation at 16100 x g using a microcentrifuge. Aliquots (35 μL) of the soluble and 
insoluble fractions in sample loading buffer (50 mM Tris-HCl pH=6.8, 10% glycerol, 2% 
SDS, 0.001% bromophenol blue, 100 mM DTT) were ran on a 12% SDS-PAGE gel. His-
DPS-L was detected in the soluble fraction and had the expected size of ~39.6KDa, as 
determined by the ExPASy Compute PI/MW tool 
(http://ca.expasy.org/tools/pi_tool.html). His-DPS-S was detected in the insoluble 
fraction, at the expected size of ~36.6 kDa (Figure A 1A).
His-DPS-L, expressed in a soluble form, was further purified by immobilized
metal affinity chromatography. The remaining soluble fraction of pET-DPS-L (~5ml) 
was prepared for purification by addition of 500 μL 10X lysis buffer (500 mM NaH2PO4,
3M NaCl, 100 mM imidazole). The lysate was added to a column containing 10 mL of 
Ni-sepharose slurry. The column was then washed eight times with 5 mL washing buffer 
(50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole). The protein was eluted with 5 mL 
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole), and 25 one-mL 
fractions were collected. Thirty-five μL of each fraction was run on a 12% SDS-PAGE 
gel. Fractions 10 and 11 contained most of His-DPS-L  (Figure A 1B). 
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Figure A 1  Protein purification of DPSS.bae
A) SDS-PAGE analysis of BL21(DE3) crude protein extracts following His-DPS-L and 
His-DPS-S expression B) Elution fractions analysis by SDS-PAGE following metal-
affinity purification of His-DPS-L.
A2. Effect of selected carbon sources on growth and CoQ10 production 
As mentioned in section 3.3.1, several attempts have been made to compare 
CoQ10 production between CC023 cultures grown on different carbon substrates. In 
addition to the experiment presented in section 3.3.1 (Figure 3.2), the following 
experiments were also documented, and are included here to illustrate the challenges 
encountered.   These experiments were conducted in fermentation medium (Tsuruta et al., 













































































2009), as described in section A4, in order to facilitate eventual comparisons between 
flask fermentations and fed-batch fermentations in bench-top fermentors. It was later 
realized that the use of fermentation medium in flask experiments was undesirable 
because of its poor buffering capacity, which resulted in high variability between 
replicate experiments. Fermentation medium was therefore replaced by M9 medium in 
experiments presented in the main body of this thesis. 
The experiment shown in Figure A 2 was done in fermentation medium, 
supplemented with 0.06 % casamino acids and 150 mM of the selected carbon source.  
Figure A 2 Growth and CoQ10 production on fermentation medium supplemented 
with casamino acids and selected carbon sources  
Strain CC023 was grown for five days with 150 mM of either glucose (squares), glycerol 
(circles), pyruvate (diamonds) or succinate (triangles). Cultures were induced with 0.5 mM 
IPTG during early exponential phase. Aliquots were taken after 0, 20, 72 and 120 hours to 
measure A) optical density and B) CoQ10 content. Error bars show the standard variation 
of three biological replicates. 
The experiment presented in Figure A 3 was done using fermentation medium, 
but only the pre-cultures were supplemented with 0.3% casamino acids. The 
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each tested condition: 17 mM glucose, 33mM glycerol, 33 mM pyruvate and 25 mM 
succinate. Because of an experimental error, only the glycerol and succinate cultures 
were induced, which should not have a significant impact on CoQ10 production based on 
my findings presented in section 2.3.8.
Figure A 3 Growth and CoQ10 production on fermentation medium supplemented 
with selected carbon sources 
Strain CC023 was grown for five days with either 33 mM glycerol (circles), 25 mM 
succinate, 33 mM pyruvate or 17 mM glucose,. Glycerol and succinate cultures were 
induced with 1 mM IPTG during early exponential phase. After five days, optical density 
and CoQ10 content were measured. Error bars show the standard variation of three 
biological replicates. 
In order to test whether different concentrations of substrate may influence 
growth and CoQ10 production in strain CC023, I then tested a range of concentrations 
(0.1%, 1% and 10%) of glucose, glycerol, pyruvate and succinate. Because the addition 
of casamino acid complicated the interpretation of carbon fluxes and appeared to 

































Figure A 4 Growth and CoQ10 production on fermentation medium supplemented 
with different concentrations of selected carbon sources 
Strain CC023 was grown for five days with 0.1%, 1% or 10% glucose, glycerol, pyruvate 
or succinate. Glycerol and succinate cultures were induced with 1 mM IPTG during early 
exponential phase. After five days, optical density and CoQ10 content were measured. 
The next experiments, performed in 96-well plates, were conducted in order to 
characterize the growth pattern of strain CC023 on the different carbon sources.  
Figure A 5 Influence of selected carbon substrates on growth of CoQ10 producing 
and control strains 
A) Strain CC023 and B) a control strain (MG1655, pTrc99A, pBBR1MCS3, pBAD33) 
were grown in triplicate in a 96-well plate incubated in a microtiter plate reader with 
continuous shaking, in fermentation medium supplemented with 16.7 mM glucose 
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(triangles). Once they reached exponential phase, cultures were induced with 0.5 mM 
IPTG. Optical densities were measured automatically by the plate reader. 
Figure A 5 demonstrates that the severe growth reduction observed on pyruvate 
and succinate is attenuate in a control strain carrying empty vectors, compared to strain 
CC023. This suggests that these carbon substrates are poorly able to sustain biomass 
production when the mevalonate and aromatic pathways are overexpressed, presumably 
because acetyl-CoA and PEP become rate-limiting (Figure 3.1). I then attempted to 
demonstrate the link between overexpression of these two pathways and growth 
reduction. To do so, I created two additional strains: CC023noARO (MG1655, ∆ispB,
pTUbiAeDPSo, pMBIS, pMtSa), which does not contain the integrated aromatic operons, 
and CC023noISO (MG1655, ∆ispB, aroB::LTAA, ubiC::LLACC, pTUbiAeDPSo,
pMBIS), which does not carry the upper mevalonate pathway. Figure A 6 shows the 
growth pattern of these two strains on glucose, pyruvate, succinate, and on medium 
containing both pyruvate and succinate, compared to that of strain CC023, and of a 
control strain (MG1655, pTrc99A, pBBR1MCS3, pBAD33). The interpretation of this 
experiment was complicated by the strong growth inhibition observed following the 
IPTG induction of the cultures. Cell densities of CC023 on pyruvate and succinate 
reached higher levels in this experiment (Figure A 6A) than it previously did (Figure A 
5A) while those of the control strain were lower (Figure A 6D) than before (Figure A 
5B). In addition, strain CC023 displayed an extended lag phase on glucose (Figure A 
6A), which had previously been observed in the experiment summarized by Figure A 4.
The strain was therefore re-built by transforming strain MG1655 ∆ispB aroB::LTAA 
ubiC::LLACC + pTUbiAeDPSo with plasmids pMBIS and pMtSA for subsequent 
experiments.  
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Figure A 6 Effect of the mevalonate and aromatic operons during growth of E. coli on 
selected carbon substrates 
Strains CC023, CC023noARO (MG1655, ∆ispB, pTUbiAeDPSo, pMBIS, pMtSa), 
CC023noISO (MG1655, ∆ispB, aroB::LTAA, ubiC::LLACC, pTUbiAeDPSo, pMBIS) and 
a control strain (MG1655, pTrc99A, pBBR1MCS3, pBAD33) were grown in triplicate in a 
96-well plate incubated in a microtiter plate reader with continuous shaking, in 
fermentation medium supplemented with 16.7 mM glucose (squares), 33.3 mM pyruvate 
(diamonds), 25 mM succinate (triangles) or a mix of 15 mM pyruvate and 13 mM 
succinate (circles). Grey symbols show when cultures were induced with 0.5 mM IPTG. 
Optical densities were measured automatically by the plate reader. 
Overall, these experiments illustrate the reproducibility and strain stability issues 
observed when characterizing growth and CoQ10 production of strain CC023 on selected 
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A3. CoQ10 production on sorbitol, as reported from 2013 experiments  
The positive effect of sorbitol on CoQ10 production in strain CC023 was 
observed in at least three independent experiments, each performed in three biological 
replicates, in July and August 2012. Upon return from maternity leave in May 2013, 
similar experiments done in identical conditions failed to yield the same results. CoQ10 
production was henceforth reduced on sorbitol compared to glucose. In addition, the 
profile of secreted metabolites was different from what had been previously documented, 
on both glucose and sorbitol. These changes were observed in repeated experiments, and 
previous results could not be reproduced by reintroducing plasmids and mutations in 
strain CC023. The accumulation of PHB was lower on glucose that what had previously 
been observed, with the excretion of only 0.004 mM PHB and no detectable PHB 
remaining in the medium by 28 hours (Figure 3.5C, Figure A 7C). When grown on 
sorbitol, strain CC023 accumulated three times more PHB than it previously did in 
similar conditions, with up to 0.015 mM of PHB accumulating in the growth medium 
(Figure 3.5C, Figure A 7C). Enhanced excretion of PHB correlated with reduced 
accumulation of CoQ10 and of Unknown 1 by cells grown on sorbitol, compared to cells 
grown on glucose, and compared to 2012 experiments (Figure 3.5A, C; Figure A 7A, C). 
Strain CC023 grown on glucose secreted less acetate that previously observed, but 
produced more lactate and pyruvate (Figure 3.5E, F; Figure A 7E, F). Cells grown on 
sorbitol produced no acetate, as previously observed (Figure 3.5A, C; Figure A 7A, C). 
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Figure A 7 Time-course of CoQ10 production and metabolite secretion during 
aerobic flask fermentation on glucose and sorbitol (2013) 
Strain CC023 was grown for five days on glucose (triangles) or sorbitol (squares), in June 
2013. Samples were taken after 0, 8, 28, 68, and 120 hours to measure A) CoQ10 (filled 
shapes) and 10P-Ph (empty shapes) content B) optical density C) extracellular PHB D)
extracellular Unknown 1 E) extracellular acetate F) extracellular lactate (filled shapes) and 
pyruvate (empty shapes). Error bars show the standard deviation of three biological 
replicates. 
A4. Accumulation of putative TCA cycle intermediates  
This section reports the accumulation pattern of an extracellular metabolite first 


















































































































































(Time-course of CoQ10 production and metabolite secretion during aerobic flask 
fermentation on glucose and sorbitol (2012)) and Figure 3.6 (Time-course of CoQ10 
production, growth, and metabolite accumulation following the deletion of acetate 
producing pathways). As other TCA cycle intermediates including oxaloacetate, 
isocitrate and α-ketoglutarate co-elute with citrate under my analytical conditions, I could 
not attest with confidence of the identity of this metabolite, and therefore chose to 
exclude it from the body of the thesis. The secretion of this putative TCA cycle 
intermediate is enhanced during growth on sorbitol and in strain CC027, in which genes 
controlling acetate production are deleted (Figure A 8, Figure A 9). Differences in 
accumulation pattern of this putative TCA intermediate between the strains/conditions 
tested provides hints regarding the fluxes directing carbon flow and CoQ10 production.  
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Figure A 8 Time-course of citrate (or other TCA intermediates) secretion during 
aerobic flask fermentation on glucose and sorbitol 
A metabolite corresponding to citrate, oxaloacetate, isocitrate and/or α-ketoglutarate 
accumulated in the growth medium following growth on glucose (triangles) or sorbitol 
(squares). Samples were taken as part of the experiment reported in Figure 3.5 Time-
course of CoQ10 production and metabolite secretion during aerobic flask fermentation on 
glucose and sorbitol (2012). Error bars show the standard deviation of three biological 
replicates. 
Figure A 9 Time-course of citrate (or other TCA intermediates) secretion during 
aerobic flask fermentation following the deletion of acetate producing pathways 
A metabolite corresponding to citrate, oxaloacetate, isocitrate and/or α-ketoglutarate 
accumulated in the growth medium following growth of strains CC023 (circles), CC026 
(squares) and CC027 (triangles) on glucose. Samples were taken as part of the experiment 
reported in Figure 3.6 Time-course of CoQ10 production, growth, and metabolite 
accumulation following the deletion of acetate producing pathways. Error bars show the 




































A5. CoQ10 production in fed-batch fermentation  
The flask experiments presented so far were done in condition where carbon is in 
excess. Growth in excess glucose may lead to the depletion of TCA cycle intermediates, 
and halt of respiratory chain, resulting in an accumulation of NADH (Wolfe, 2005). The 
accumulation of pyruvate in strain CC028 led to the hypothesis that pyruvate 
dehydrogenase had decreased activity. This enzyme complex, which converts pyruvate to 
acetyl-CoA, is inhibited by NADH (Schmincke-Ott and Bisswanger, 1981). Fed-batch 
fermentation has the advantage of maintaining glucose levels limiting, thereby 
minimizing mixed-acid fermentation and maximizing aerobic respiration. I tested the 
production of CoQ10 by CC028 under these conditions. To ensure that the rate of 
supplied glucose did not exceed the growth rate, and that carbon was not metabolized 
into mixed-fermentation products, a pH-stat controlled the feed pump by switching the 
latter off when pH went down below a set value.  
A pH-stat fed-batch fermentation was done based on the process described by 
Tsuruta et al. (2009). Strain CC028 was streaked on M9 solid medium supplemented 
with 2% glucose and grown for two days. Several colonies were used to inoculate 5 mL 
pre-cultures in M9 medium supplemented with 3 % glucose and appropriate antibiotics. 
Following 48 hours of growth, pre-cultures were spun down and adjusted to an OD600 of 
1, and used to inoculate 100 mL of M9 (3% glucose) medium in a 1L-baffled flask. This 
seed culture was grown for 6 hours, and then used to inoculate a 2L bioreactor 
(Applikon).  The initial fermentation medium consisted of 1.3 L containing 5.46 g 
KH2PO4, 20.41 g K2HPO4, 2.6 g (NH4)2SO4 and 2.21 g citric acid prepared and sterilized 
in the fermentor vessel. Post sterile additions, prepared as filter-sterilized concentrated 
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stocks, consisted of 1.5% glucose, 1.2 g MgSO4·7H2O, 4.5 mg thiamine·HCl, 8.4 mg 
EDTA, and 10 mL of batch trace metal solution containing (per liter) 0.136 g CoCl2, 1.5 
g MnCl2·4H2O, 0.12 g CuCl2, 0.3 g H3BO4, 0.25 g Na2MoO4·2H20, 1.3 g 
Zn(CH3COO)2·2H20, and 10 g Fe(III) citrate hydrate (Tsuruta et al., 2009).  Antibiotics 
were also added for plasmid retention. Fermentation was carried out at 37°C, and the pH 
maintained at 7 using automated addition of 0.25% v/v NH4OH or 1M HCl. The initial 
agitation rate was set to 700 rpm, and the air flow to 1.5 air volume/vessel 
volume/minute. Dissolved oxygen was maintained above 40% of air saturation by an 
agitation cascade from 700 to 1000 rpm, followed by the addition of pure oxygen by a 
mass flow controller. A 25% v/v solution of Antifoam A (Sigma-Aldrich) was used to 
control foam. Following the exhaustion of the initial glucose, a sharp rise in dissolved 
oxygen above 60% triggered the onset of an exponential feed. The following equation 
was used by the fermentor software (BioXpert) to control feed rate: ms(t)= Soμeμ(t-t0),
where So is the initial glucose concentration (15 g/L), μ is the specific growth rate (0.12h-
1) and to is the time of glucose depletion from the batch medium. Once the feed rate 
reached 31 g glucose/h, it was reduced to 11.7 g/h and held constant for the remainder of 
fermentation. The feed rate was additionally controlled by a pH-stat, turning feed off 
when pH dropped below 6.96. The culture was induced with 0.1 mM IPTG after the onset 
of the fed-batch phase. 
After an extended lag phase, the strain grew to high density, reaching an OD600 of 
44 (Figure A 10B). Initial glucose was entirely consumed after 20 hours, and the resulting 
rise of dissolved oxygen triggered the onset of the fed-batch phase (Figure A 10B). 
During exponential phase and up to 32 hours, dissolved oxygen oscillated around 40%, 
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after which it went up to 80%, suggesting decreased respiration. After 72 hours, the filter 
of the air outlet of the fermentor became obstructed by water and bacteria, causing a 
sharp rise of pressure in the fermentor vessel, which stopped the fermentation. This 
problem was encountered multiple times during experiments using this fermentor, and 
has hampered my attempts to perform sustained fermentations. Secretion of PHB 
remained undetectable during the initial batch phase, and reached 0.16 mM by 64 hours 
(Figure A 10C). Similarly, Unknown 1 accumulated only during the fed-batch phase 
(Figure A 10D). Considering the cell densities reached during this experiment, the 
secretion of Unknown 1 appeared to be increased by ten-fold compared to previous flask 
experiments. Pyruvate accumulation reached approximately 40 mM by the end of the 
fermentation, which is lower than what was secreted by strain CC028 in flask 
experiments, when normalizing to cell mass (Figure 3.7H, Figure A 10E). This supports 
the initial hypothesis that pyruvate secretion by strain CC028 is linked to the inhibition of 
pyruvate dehydrogenase by high NADH concentrations. Nevertheless, CoQ10 contents 
stayed low throughout the fermentation, reaching only 0.3 mg/g DCW (Figure A 10A).
The accumulation pattern of PHB suggests that the expression of the engineered 
pathways is mainly active when respiratory rates are lower, during the fed-batch phase. 
Similarly to flask fermentations where the CoQ10 production phase extends for several 
days into the stationary phase, it is possible that CoQ10 might have continued to 
accumulate if fed-batch fermentation could had been sustained for more than 72 hours. 
However, I also suspect that the extended lag phase favored the apparition of point-
mutants which out-competed strain CC028 during the exponential phase. This would be 
consistent with the high variability observed between replicates during flask fermentation 
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experiments. Further optimization of my engineered strain and of the fermentation 
process will be required before fed-batch fermentation can be used a tool to increase 
CoQ10 production. 
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Figure A 10 Fed-batch fermentation for CoQ10 production 
Strain CC027 was grown for 72 hours in a bench-top fermentor. Following the exhaustion 
of initial glucose, fed-batch fermentation was initiated and controlled by a pH-stat. 
Samples were taken after 20, 26, 39, 49, 64 and 72 hours to measure A) CoQ10 content C)
secreted PHB D) secreted Unknown 1 E) secreted acetate. B) Optical density was measured 
every minute using a Bug Eye. F) Dissolved oxygen was recorded every minute using 
BioExpert. 
A6. Identification of Unknown 1 
Unknown 1 is an unidentified metabolite secreted by engineered strains of E. coli,
with an accumulation pattern closely correlated to that of CoQ10 (Figure 3.5D, Figure 

































































































































Unknown 1 by mass spectrometry. To this end, samples (20 μL) previously established as 
containing high concentrations of Unknown 1 were resolved by HPLC, using  an Aminex 
HPX-87H column (Bio-Rad) heated at 65°C, and a mixture of 85% H2SO4 and 15% 
acetonitrile as the mobile phase, at 0.6 mL/minute. Unknown 1 eluted after 13.7 minutes, 
and was detected by a PDA detector at 254 nm and 210 nm. The eluent from the PDA 
detector was collected in a 1.5 mL tube. Different attempts were made to identify 
Unknown 1 from the collected fraction. 
In a first attempt, Unknown 1 was collected from the supernatant fraction of a 
sample taken after 72 hours of fed-batch fermentation of strain CC028 (section A5). In 
this sample, Unknown 1 eluted 0.4 minutes after an undetermined amount of mevalonate, 
which absorbs at 210 nm but not at 254 nm. The collected fraction was evaporated in a 
speed vacuum concentrator and suspended in 0.1% formic acid. A 10 μL aliquot of this 
suspension was analyzed by LC-MS, using a Fast Acid Analysis column (Bio-Rad) 
heated at 65°C, using 0.1% formic acid and 15 % acetonitrile as the mobile phase.
Resolved molecules were channeled to a Fourier Transform Ion Cyclotron Resonance 
Mass Spectrometer (FTMS), scanning between m/z=50 and m/z=350, at r=100,000 @ 
m/z=400.  
Consistently with the co-elution of mevalonate with Unknown 1 in the collected 
sample, mevalonolactone was identified by FTMS (Figure A 11). The additional ions 
detected by LC-FTMS could not be associated with known metabolites of E. coli.
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Figure A 11 Identification of Unknown 1 from the supernatant fraction of a culture of 
strain CC028 after 72 hours of fed-batch fermentation 
A) Unknown 1 was detected at 210 nm and 254 nm after 13.693 minutes of HPLC analysis, 
and is marked by a star on the chromatogram. B) Spectra of detected ions following LC-
FTMS analysis of a collected fraction of Unknown 1. The protonated ion labeled as 
C6H11O3 [M+H]+=131.0699 corresponds to mevalonolactone (exact mass = 130.0630). The 
protonated ion labeled as C2H12O5N7 [M+H]+=214.0891 corresponds to a contaminant 
present throughout the analysis. The protonated ions m/z=113.0594, m/z=172.0965 and 
m/z=190.1070 could not be associated with known E. coli metabolites. 
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In a second attempt, Unknown 1 was collected from the supernatant fraction of a 
sample taken after 120 hours of flask fermentation of strain CC023. A Control sample 
was collected between 18.1 and 18.4 minutes of analysis, as no detectable peaks at 254 
nm were visible during this time window. The Unknown 1 and Control fractions were 
each spiked with 5 μg/ml of CoQ10, as an internal control. A 100 μL sample from each 
collected fraction (500 μL) was saved for analysis. The remaining 400 μL of each sample 
was extracted with one volume of hexane, in order to extract putative quinone 
intermediates. The hexane fraction of each sample was evaporated in a nitrogen stream 
and suspended in acetone. The aqueous fraction of each fraction was also analyzed. All 
fractions were analyzed by RP-HPLC using the quinone analysis method described in 
section 2.2.11, and were detected at 254 nm. No absorption peak was detected from the 
Unknown 1 and Control fractions, except for the CoQ10 internal standard. Samples were 
then analyzed by LC-FTMS, using the quinone analysis method previously described,
and scanning by FTMS between m/z=50 and m/z=1500, at r=100,000. No ions were 
detected in the Unknown 1 fractions that were absent from corresponding Control 
fractions (not shown). This suggests that Unknown 1 is not retained by reverse-phase 
chromatography (ZORBAX Eclipse XDB-C18 4.6 x 150 mm, 5 μm), and that it is not a 
quinone intermediate or derivative. 
In conclusion, my attempts to identify Unknown 1 remained unfruitful. Additional 
work will be required to ensure that the isolation of Unknown 1 from biological samples 
is effective, and that appropriate analytical methods are developed.   
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